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Riassunto 
 
“Interazioni proteiche mediate da domini α-elicoidali” 
 
Uno degli aspetti più interessanti ed impegnativi nella moderna ricerca biotecnologica 
riguarda la comprensione, a livello molecolare delle funzioni cellulari attraverso lo 
studio delle relazioni struttura-funzione delle proteine. L’importanza nell’ampliare le 
informazioni sull’attività biologica di singole proteine, risiede nella possibilità di 
controllarne i meccanismi di azione a livello cellulare e di prevederne gli effetti. Molti 
processi non sono controllati soltanto dall’abbondanza relativa delle varie proteine, 
ma anche dalla regolazione transiente della loro attività mediante, ad esempio, 
modificazioni covalenti reversibili e da interazioni non covalenti tra fattori proteici 
all’interno della cellula. Gli studi di proteomica funzionale e di biologia strutturale che 
studiano questi processi, sono dedicati all’approfondimento delle conoscenze dei 
meccanismi fisiopatologici legati alle interazioni proteiche ed alla progettazione 
razionale di farmaci da usare per combattere malattie in rapida diffusione. E’ infatti 
noto che numerose patologie che vanno dalle più comuni disfunzioni metaboliche a 
malattie quali la tubercolosi e la malaria, alle più svariate forme tumorali, sono 
strettamente correlate a fattori di natura proteica ed alle loro interazioni con molteplici 
partner molecolari che propagano i segnali di innesco iniziali (trasduzione del 
segnale).  
Uno dei meccanismi biomolecolari più importanti è proprio la trasduzione di questi 
segnali, innescati generalmente da specifiche interazioni di proteine extracellulari con 
recettori transmembrana, propagate all’interno della cellula sia da altre interazioni 
proteina-proteina sia da più complessi meccanismi enzimatici. Tali interazioni si 
traducono in eventi molecolari che portano all’attivazione di fattori di trascrizione 
attraverso complesse cascate amplificative. Alcuni meccanismi regolano l’intero ciclo 
vitale della cellula e sono la risultante di un complesso “balancing” di opposti segnali 
di sopravvivenza cellulare (anti-apoptotici) o di morte cellulare programmata (pro-
apoptotici) che sono regolati dal riconoscimento tra specifici domini proteici, per 
questo denominati “Death domains” (DD). La segnalazione dell’apoptosi si avvale per 
lo più di interazioni omofiliche tra DD di recettori di superficie e proteine adattatrici 
intracellulari che determinano l’attivazione di proteasi specifiche (caspasi). Tale 
attivazione determina una cascata di eventi proteolitici e nucleolitici che amplificano il 
segnale e portano alla morte cellulare. Un’alterazione nei processi mediati da fattori 
proteici coinvolti nell’apoptosi è responsabile, ad esempio, della formazione di tumori 
quali il linfoma gastrico di tipo MALT (Mucosa-Associated Lymphoid Tissue). La 
sovraespressione del fattore Bcl10 nel nucleo e nel citoplasma dei linfociti B porta ad 
un’alterazione del segnale di attivazione del fattore NF-κB, con conseguente 
alterazione dei meccanismi di morte cellulare programmata e sviluppo del linfoma. Il 
meccanismo di azione cellulare di tale fattore è tuttora oggetto di numerosi studi. 
Un altro aspetto interessante nello studio dei meccanismi cellulari proteina-mediati 
risiede nello studio delle interazioni di fattori proteici con la parete cellulare batterica. 
E’ noto che la maggior parte di antibiotici e antimicrobici agisce a livello della 
biosintesi del peptidoglicano, il principale costituente della parete batterica, o 
modificando la permeabilità di quest’ultima. Recenti studi rivelano che anche le 
interazioni di alcuni fattori proteici con la parete cellulare rivestono un ruolo cruciale 
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in processi patologici, quali ad esempio la tubercolosi, una malattia, ancora oggi, di 
altissimo impatto sociale. Il trattamento della tubercolosi, è seriamente compromesso 
dai fenomeni di resistenza ai comuni antibiotici sviluppati dal batterio responsabile, 
Mycobacterium tuberculosis. Pertanto, è pressante la richiesta di nuovi farmaci, che 
consentano di potenziare i trattamenti attualmente in uso.  
La capacità di tale batterio di permanere in uno stato di latenza nell’organismo 
ospite, per poi attivare i propri effetti patologici dopo lungo tempo, ne fa ancora oggi 
una delle principali cause di morte in molti pesi del mondo.  
Studi recenti su Mycobacterium tuberculosis hanno identificato fattori proteici in 
grado di “resuscitare” il batterio dal suo stato di latenza. Tali proteine, mediante un 
meccanismo di azione simile a quello descritto per il lisozima, idrolizzano 
parzialmente la parete cellulare determinando la riattivazione delle funzioni 
patologiche del batterio. Il meccanismo che determina la transizione del batterio dallo 
stato di latenza a quello patologico non è stato ancora chiarito, e non è noto se la 
parziale degradazione della parete batterica determini l’attivazione di altri fattori. La 
possibilità di dare una risposta a questi interrogativi fa delle proteine coinvolte in tali 
meccanismi un interessante argomento di studio. 
 
Il presente lavoro di tesi si propone lo studio di due tipi di interazioni proteiche 
coinvolte in meccanismi patologici: le interazioni omotipiche fra domini di proteine  
coinvolte nella formazione di linfomi e le interazioni di fattori proteici con la parete 
cellulare del batterio responsabile della tubercolosi, allo scopo di chiarire i 
meccanismi di riattivazione della patogenesi del batterio nel suo stato di latenza. Tali 
studi sono volti ad una migliore comprensione dei meccanismi molecolari che 
regolano i processi patologici citati con lo scopo di individuare nuovi e più specifici 
“target” di azione farmacologica. 
 
La prima parte del lavoro di tesi è incentrata sulla caratterizzazione strutturale e 
funzionale del dominio CARD (Caspase-recruitment domain) del fattore proteico 
Bcl10. Sulla base di recenti dati di letteratura è emerso che la sovraespressione di 
tale proteina è legata allo sviluppo di linfomi di tipo MALT ed è determinata da una 
traslocazione genica che pone il gene bcl10 sotto il controllo del gene promotore 
delle catene pesanti delle immunoglobuline. Il meccanismo attraverso il quale la 
sovraespressione di Bcl10 conduca all’oncogenesi è attualmente sconosciuto. E’ 
noto, tuttavia, che il gene “wild-type” bcl10 codifica per una proteina contenente un 
dominio CARD N-terminale, mediante il quale Bcl10 interagisce con domini uguali, 
presenti in altri fattori proteici, attivando il fattore NF-κB e promuovendo l’apoptosi.  
Modificazioni morfologiche o mutazioni a livello del dominio CARD si riflettono nella 
perdita di capacità, da parte della proteina, di indurre apoptosi e, conseguentemente, 
nello sviluppo del tumore. E’ stato inoltre riportato che Bcl10 è in grado di 
assemblarsi in filamenti all’interno del citoplasma, mediante un processo di 
omodimerizzazione tra domini CARD di molecole contigue. La formazione di filamenti 
avviene a seguito della dimerizzazione CARD/CARD e questa organizzazione 
porterebbe all’attivazione del fattore NF-κB.  
Sebbene la struttura del dominio CARD di Bcl10 non sia stata ancora determinata, è 
nota la struttura cristallografica ed NMR di altri CARD che presentano una discreta 
identità di sequenza con quello appartenente a Bcl10. Il dominio, presente nella 
regione N-terminale della proteina, è costituito da sei α-eliche con un arrangiamento 
tipico a chiave greca ed ha una lunghezza di circa 110 residui amminoacidici. Le 
interazioni mediate da CARD sono da attribuire ad interazioni di tipo idrofobico tra 
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eliche, tuttavia, uno studio sulle regioni imputate a tali interazioni non è mai stato 
riportato in letteratura. Nel presente lavoro di tesi si è studiato un mutante del 
dominio CARD, ottenuto per via ricombinante, con le uniche due cisteine presenti 
nella sequenza, sostituite da serine. Tale dominio è stato caratterizzato in soluzione 
mediante tecniche di dicroismo circolare per verificarne il folding, e, 
successivamente, è stato condotto uno studio per verificarne la tendenza associativa 
in forma di omodimero.  
Da questi esperimenti preliminari è stato possibile studiare l’equilibrio monomero-
dimero in soluzione e derivare il calcolo della costante di dissociazione del dimero. Il 
valore di tale costante è stato derivato considerando la variazione di un parametro 
spettroscopico (in questo caso l’ellitticità molare) in dipendenza della concentrazione 
di CARD. Il valore ottenuto è di 18.6 µM. Si è inoltre osservato che ad un aumento 
della concentrazione di CARD in soluzione corrisponde uno spostamento 
dell’equilibrio verso la forma dimerica ma, inaspettatamente, anche una perdita di 
strutturazione da parte del dominio che passa da un folding prevalentemente di tipo α 
elicoidale ad una forma di tipo random. Successivamente, l’interazione CARD/CARD 
è stata verificata con saggi ELISA immobilizzando il dominio su piastra e 
monitorando l’associazione con lo stesso dominio derivatizzato con la biotina, 
utilizzando il sistema di rilevazione biotina-streptavidina. Una volta verificata 
l’associazione, allo scopo di identificare le regioni della sequenza di CARD 
responsabili di tali interazioni omotipiche,  il dominio è stato digerito con tripsina e le 
frazioni di digerito sono state utilizzate per un saggio di competizione ELISA. I 
frammenti triptici di CARD, che competono nell’interazione con il dominio intero, sono 
stati selezionati e caratterizzati mediante LC-MS. 
Allo scopo di caratterizzare le regioni di interazione tra domini CARD individuate 
mediante i saggi sul digerito triptico, tali frammenti sono stati ottenuti per via sintetica 
con strategie di sintesi peptidica in fase solida. Il frammento CARD [127-134] e due 
suoi analoghi di sequenza più estesa, CARD [104-134] e CARD [114-134], sono stati 
sintetizzati e la loro attività come modulatori dell’interazione omotipica è stata 
verificata con successo mediante un saggio ELISA di competizione analogo a quello 
utilizzato per testare i frammenti triptici. Successivamente, è stata effettuata la 
caratterizzazione al dicroismo circolare sui frammenti sintetici per rivelarne le 
preferenze conformazionali in soluzione. Dagli spettri acquisiti a 20°C e a due 
differenti valori di pH (4.5 e 7.5), si osserva che il frammento CARD [104-134] adotta 
in soluzione un folding di tipo α-elicoidale in entrambe le condizioni sperimentate. Si 
è inoltre osservato che, tale folding è molto stabile, anche a temperature superiori ai 
40°C. Un preliminare studio NMR è stato effettuato sul frammento a diverse 
concentrazioni e diverse temperature ed è stato possibile definire che il peptide 
rimane stabile e non subisce aggregazione fino a concentrazioni pari a 0.3 mM. 
Ulteriori esperimenti NMR sono attualmente in corso per la determinazione della 
struttura di tale frammento il soluzione. Inoltre, esperimenti in vitro per testarne la 
capacità di inibire la formazione dei filamenti citoplasmatici che si formano a seguito 
di interazioni CARD/CARD, sono stati programmati e forniranno un importante 
contributo alla comprensione del meccanismo che conduce all’oncogenesi. 
 
La seconda parte del presente lavoro di tesi è dedicata allo studio delle interazioni di 
proteine con la parete batterica, coinvolte nei meccanismi di resistenza del batterio 
M. tuberculosis. E’ noto che tale batterio patogeno è in grado di entrare in uno stato 
di latenza, in cui non si verifica replicazione e tutte le attività metaboliche sono 
ridotte. In tale stato il batterio può rimanere inattivo per lunghi periodi, finchè un 
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evento di “resuscitazione” lo riporta nella sua forma patogenica. I farmaci antibiotici 
attualmente impiegati per combattere la patologia agiscono solo sul batterio attivo e 
quindi quando la patologia è già in atto. Una maggiore comprensione dei meccanismi 
alla base del processo che porta il batterio fuori dallo stato di latenza è in questo 
caso di fondamentale importanza per poterne contrastare gli effetti. Il primo fattore 
proteico denominato “Resuscitation-promoting factor” (Rpf) perchè in grado di 
“resuscitare” colture in stato di latenza è stato individuato in Micrococcus luteus. 
Tuttavia, mentre in M. luteus è presente un solo gene codificante per tale fattore, M. 
tuberculosis così come altri organismi appartenenti alla stessa famiglia M. bovis e M. 
leprae, possiede cinque geni codificanti per altrettante proteine denominate Rpf A-E. 
Tali proteine presentano una discreta omologia di sequenza con quella identificata in 
M. luteus ed hanno in comune un dominio C-terminale altamente conservato, di circa 
80 residui amminoacidici. La struttura NMR di tale dominio, ottenuta per il fattore Rpf 
B, rivela la presenza di 4 α-eliche ed un folding analogo a quello del lisozima. 
L’attività muralitica sembra essere alla base del meccanismo di “resuscitazione” del 
batterio. Recenti studi condotti su Rpf di M. luteus hanno infatti dimostrato che tale 
fattore proteico ha attività paragonabile a quella del lisozima e, tale attività, 
coinvolgerebbe il suo dominio C-terminale mentre, lo stesso dominio, nelle Rpf di M. 
tuberculosis sembrerebbe non possedere attività muralitica. 
Nel presente lavoro di tesi si è dimostrato che un’analoga attività è presente anche in 
Rpf B da M. tuberculosis. Allo scopo di approfondire le conoscenze sul meccanismo 
di azione delle Rpf in M. tuberculosis, sono state selezionate due proteine da tale 
organismo: Rpf B ed Rpf C. La scelta è stata dettata da uno studio preliminare della 
struttura primaria e su predizioni di struttura secondaria ottenute con metodi 
bioinformatici. Con l’intento di effettuare una caratterizzazione strutturale, oltre che 
funzionale, di tali proteine, sono state selezionate le sequenze prive di regioni ricche 
in proline ed alanine, problematiche per il folding della proteina. Sono state quindi 
prese in considerazione le proteine Rpf B ed Rpf C che fra tutte le Rpf di tuberculosis 
meglio si prestavano a tali studi. Entrambe le proteine sono state clonate, espresse 
in E. coli e purificate, sia nella forma “full length” che in una forma troncata in cui, un 
breve segmento N-terminale di 30 residui, identificato come potenziale peptide 
segnale, è stato rimosso per aumentare le rese di proteina solubile. E’ stato inoltre 
clonato, espresso e purificato il solo dominio C-terminale della proteina Rpf B, 
denominato Rpf Bcd in quanto costituisce il dominio catalitico della proteina. Una 
caratterizzazione in soluzione con tecniche di dicroismo circolare è stata effettuata 
per Rpf B e il suo dominio catalitico e per  Rpf C. Gli spettri ottenuti rivelano che Rpf 
B ed Rpf C hanno entrambe propensione ad adottare un folding di tipo α-elicoidale, 
sebbene Rpf B sia più strutturata, nelle condizioni di pH e concentrazione 
sperimentate. Anche il dominio C-terminale Rpf Bcd ha un folding di tipo α-elicoidale. 
Per Rpf B ed Rpf Bcd sono stati effettuati esperimenti per verificare la stabilità delle 
proteine monitorando allo spettropolarimetro la perdita di strutturazione a seguito di 
un aumento della temperatura da 5°C a 80°C, e la capacità della proteina in esame 
di riacquistare il folding iniziale in seguito a raffreddamento a 5°C. Da tale studio 
emerge che, tanto la proteina, quanto il dominio Rpf Bcd hanno una buona stabilità in 
quanto, il carattere α-elicoidale viene perso, a seguito dell’unfolding, in modo quasi 
del tutto reversibile. E’ possibile infatti paragonare gli spettri di dicroismo circolare 
delle proteine nello stato iniziale e dopo refolding. Successivamente, allo scopo di 
verificare l’attività muralitica di Rpf B ed Rpf C, sono stati effettuati esperimenti 
preliminari di “Dynamic Light Scattering” (DLS) per escludere la presenza di forme 
aggregate, che avrebbero potuto interferire con l’eventuale catalisi, come riportato in 
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letteratura per studi analoghi. Tali esperimenti hanno dimostrato che la preparazione 
di Rpf B non presentava aggregati mentre per Rpf C è stato possibile individuare una 
minima percentuale di aggregazione. Per questo motivo, i successivi studi di attività, 
sono stati focalizzati sulla sola Rpf B. L’attività muralitica della proteina, è stata quindi 
testata, utilizzando il substrato artificiale del lisozima, il 4-metilumbelliferil-β-D-
N,N’,N”-triacetilchitotrioso (MUF-tri NAG). Tale substrato è costituito da tre unità di N-
acetilglucosammina (NAG), uno dei componenti essenziali del peptidoglicano che 
costituisce la parete cellulare, e dal 4-metilumbelliferone (MUF), un composto 
fluorogenico la cui presenza può essere rivelata in soluzione monitorando, allo 
spettrofluorimetro, l’emissione ad una determinata lunghezza d’onda. L’attività 
catalitica del lisozima è generalmente verificata a seguito della produzione del 
composto fluorogenico, eccitando la molecola ad una lunghezza d’onda di 360 nm e 
verificando l’emissione a 455 nm.  
Dagli esperimenti di fluorescenza effettuati sulla proteina incubata a 37°C si osserva 
un incremento dell’intensità di fluorescenza a 455 nm, più evidente nell’arco delle 
prime tre ore di incubazione. L’incremento dell’ intensità di emissione a 455 nm 
corrisponde ad un progressivo aumento della concentrazione di composto 
fluorogenico prodotto dall’idrolisi del substrato ad opera della proteina testata. 
Ulteriori esperimenti sono in corso per dare una stima quantitativa dell’attività 
muralitica della proteina Rpf B e del suo dominio Rpf Bcd, paragonando l’attività 
osservata a quella del lisozima, sullo stesso substrato.  
Gli stessi esperimenti di attività saranno effettuati sulla proteina Rpf C a seguito 
dell’ottimizzazione delle condizioni di stabilità della proteina in soluzione e, 
successivamente paragonati con i risultati ottenuti per Rpf B. 
Per entrambe le proteine sono attualmente in corso prove di cristallizzazione per 
determinarne la struttura cristallografica. La determinazione dalla struttura servirà 
anche ad individuare la regione del dominio α-elicoidale responsabile dell’interazione 
con il substrato e a fornire ulteriori chiarimenti sul meccanismo di reazione. 
Le prospettive future di questo studio sono inoltre rivolte verso la progettazione di 
test in vitro delle proteine Rpf B ed Rpf C su colture in stato di latenza per testarne 
l’attività promotrice della “resuscitazione” e progettare eventuali test di molecole 
potenzialmente inibitrici. 
 
 
 
 
 
 
 
 
 
 
 
 
 8
Summary 
 
“Protein interactions mediated by α-helical domains” 
 
A recent and exciting topic in the biotecnological research is the exploitation of a 
better knowledge of protein-protein interaction for the design of new pharmaceuticals.  
An intriguing challenge is to understand how interaction domains cooperate to 
establish the complex signaling networks, controlling events as fundamental as cell 
development, homeostasis and immune system function. Furthermore, other 
interaction types such as protein-membrane and protein-cell wall, are a challenging 
issue of investigation because of the involvement of these interactions in crucial 
mechanisms of cell homeostasis and related pathological processes. 
In this thesis work, two important issues are developed: the role of protein-protein 
interactions in dysregulation of the apoptotic signal leading to MALT lymphoma, and 
the role of protein-cell wall interactions in Mycobacterium tuberculosis reactivation 
from latency. 
The first part of this study is dedicated to a complete investigation on the 
homodimerization of the human protein Bcl10, caused by homophilic interactions 
between α-helical domains named as “Caspase-Recruitment Domains” (CARD). The 
structural behaviour of such a domain was studied by focusing the investigation on 
the domain regions, potentially involved in CARD/CARD self-association. The 
understanding of the dimerization mechanism, and how it can be modulated, is 
essential for the developing of tumour suppressor molecules.  
The results obtained, provide an investigation on CARD dimerization properties, and 
the identification of one of the region sequences involved in its self-association, the 
fragment CARD [78-98]. Preliminary NMR studies were carried out, in order to obtain 
the solution structure of this fragment. 
The second part of this thesis work is focused on the importance of protein-cell wall 
interactions in the transition of Mycobacterium tuberculosis from a latent state to a 
pathological state. With this aim, the study is devoted to the structural/functional 
characterisation of proteins from the bacterium Mycobacterium tuberculosis which 
are key players for its pathogenic activity. The main systems under investigation are 
two proteins (“Resuscitation-Promoting Factors”, named as Rpf). The role of Rpf 
proteins in the revival of dormant bacteria, still not clear, has been suggested to be 
the cleavage of oligosaccharides constituting the bacterial cell wall. All the studies 
reported so far in literature evidenced a muralytic activity, similar to that of the c-type 
lysozyme. 
The proteins Rpf B, Rpf C and the catalytic domain Rpf Bcd were cloned, expressed 
and purified. In view of Rpf B’s structural similarity to lysozyme and in order to verify 
the muralytic activity of the protein, the synthetic, artificial lysozyme substrate, was 
used for activity assays. This work has evidenced that Rpf B possesses significant 
muralytic activity. Further studies will be aimed to design Rpfs’ inhibitors, which may 
prevent the pathogen to exit its dormant state. In vitro assays will be performed by 
screening a complete library of compounds, in order to identify those able to inhibit 
the muralytic activity observed so far.  
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Abbreviation index 
 
Apaf 1: Apoptotic Protease-Activating Factor 1 
BCL10: B-cell lymphoma 10 
BSA: Bovine Serum Albumin  
CARD: Caspase Recruitment Domain 
CC-CARD: coiled-coiled caspase recruitment domain 
CD: Circular Dichroism 
DLS: Dynamic Light Scattering 
CMI: Cell mediated immunity   
DD: Death Domain  
DED: Death Effector Domain  
DMF: N,N-dimethylformamide  
DT : Diffusion Coefficient 
DTT: 1,4-Dithiothreitol 
ELISA: Enzyme-Linked Immunosorbent Assay 
FPLC: Fast Protein Liquid Chromatography 
HPLC: High Performance Liquid Chromatography 
HRP: horseradish peroxidase  
IPTG: isopropyl-beta-D-thiogalactopyranoside 
LC: long-chain 
LC-MS: Liquid Chromatography-Mass Spectrometry 
LB: Luria-Bertani 
MAGUK: Membrane-Associated Guanylate Kinase 
MALT:  Mucosa-Associated Lymphoid Tissue  
MALT1: Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 
MTB: Mycobacterium tuberculosis 
MUF tri-NAG: 4-methylumbelliferyl-β-D-N, N’, N”-triacetylchitotriose  
NAG: N-acethylglucosamine 
NBD: Nucleotide-Binding Domain 
NF-kB: Nuclear Factor-kB 
NHS: N-hydroxysuccinimide 
NMR: Nuclear Magnetic Resonance 
NTA: nitrilotriacetic acid 
OD600: Optical Density at 600 nm 
OPD: ortophenyldiamine 
PBS: Phosphate Buffered Saline 
PCR: Polymerase Chain Reaction 
PDB: Protein Data Bank 
PMSF: Phenylmethylsulphonylfluoride (Inhibitor of Serine proteases) 
RH : Hydrodynamic Radius  
RP-HPLC: Reverse Phase-High Pressure Liquid Chromatography 
Rpf: Resuscitation-promoting factor 
SD: Shine-Dalgarno  
TB: tuberculosis 
TEV: Tobacco Etch Virus (TEV) NIa protease 
TFA: Trifluoroacetic acid 
TIS:  triisopropylsilane 
TNF-α: Tumor Necrosis Factor-α 
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TPCK: Tosyl Phenylalanyl ChloromethylKetone 1-Chloro-3-tosylamido-4-phenyl-2-
butanone (irreversible inhibitor of chimotrypsin) 
Tris: Triisopropylsilane 
tri-NAG: N, N’, N”-triacetylchitotriose  
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1.       Introduction 
 
1.1     Protein interactions mediated by α-helical domains 
 
The rapidly evolving field of protein science has now come to realize the ubiquity and 
importance of protein-protein interactions. It had been known for some time that 
proteins may interact with each other to form functional complexes, but it was thought 
to be the property of only a handful of key proteins. However, protein-protein 
interactions at an organism level, are the norm and not the exception. Thus, protein 
function must be understood in the larger context of the various binding complexes 
that each protein may form with interacting partners at a given time in the life cycle of 
a cell. Proteins are now seen as forming sophisticated interaction networks subject to 
remarkable regulation. The study of these interaction networks and regulatory 
mechanism, is one of the most challenging fields of proteomics. Characterizing the 
interactions of proteins in a given cellular proteome, will be the next milestone along 
the road to understanding the biochemistry of the cell. 
The study of proteins impacts directly on human health. Indeed, enzymes, receptors, 
and key regulator proteins have been targeted for decades for drug discovery. 
However, a recent and exciting development is the exploitation of a better knowledge 
of protein-protein interaction for the design of new pharmaceuticals. Furthermore, 
other interaction types such as protein-membrane and protein-cell wall, are a 
challenging issue of investigation because of the involvement of these interactions in 
crucial mechanisms of cell homeostasis and related pathological processes. Most 
common antibiotics interfere with the bacterial cell wall, consisting of a mesh-type 
peptidoglycan polymer (murein). Cell wall plays a fundamental role in protecting of 
the bacteria from outside. In addition, it provides the organism with the necessary 
rigidity to withstand considerable osmotic pressure. According to the type of bacteria, 
the cell wall has different architecture and even mediates important mechanisms of 
resistance. Hence bacterial cell walls are an excellent target for antimicrobial therapy, 
studies on the interactions occurring with molecules and protein factors are of great 
interest in molecular and medical biotechnologies. 
This thesis work aims to provide insights on two important pathological mechanisms 
involving protein interactions with either other proteins of with the cell-wall.  
The first part of the study is focused on the protein-protein interactions occurring in 
cellular signal transduction and leading to the activation of specific transcription 
factors through complex cascades. These pathways result in a fine balancing of 
opposite signals of cell survival (anti-apoptotic signals) and cell programmed death 
(pro-apoptotic signals). The signaling key word is in the interactions between 
proteinaceous factors, mediated by specific α-helical domains, called as “Death 
Domains”. The interactions occurring between such domains are most likely 
homophylic and, as the recognition of similar domains as domains oligomerization, 
allow the activation of transduction signals. Alterations in these pathways leads to 
alterations in apoptosis signals and, consequently, to oncogenesis, as observed in 
MALT lymphomas. This part of the thesis work provides a structure-function 
characterization of a domain of the human protein Bcl10, named as CARD. This 
domain is involved in dysregulation of the apoptotic signaling and in the development 
of MALT lymphoma. 
Going further in protein interactions investigations, the second part of this thesis work 
is dedicated to the study of proteins interacting with the bacterial cell wall. The 
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bacterium under investigation is Mycobacterium tuberculosis, the organism 
responsible for the diffusion of tuberculosis, which is one of the biggest bacterial 
pathologies in the world. The aim is to clarify how this interaction activates the 
bacterium from a latent, non replicating state to the pathological state. The 
understanding of the mechanisms that regulate the route through the latent state is of 
fundamental importance for the development of new therapies. Indeed, inhibition of 
the process of exit from latency would keep the bacterium in a non pathologic, 
“dormant” state. 
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2.I      Protein-protein interactions: insights into signal transduction 
 
2.I.1    Introduction 
 
Modular protein interaction domains play an important role in signal transduction by 
mediating the assembly of components into specific signaling complexes. The 
interchange of protein modules between signaling molecules has allowed nature to 
evolve new signal transduction pathways responding to specific stress and 
developmental stimuli. 
The cytoplasmic proteins that convey information from cell surface receptors to their 
intracellular targets are commonly constructed of modular domains, that either have a 
catalytic function (such as protein or lipid kinase activity), or mediate the interactions 
of proteins with one another, or with phospholipids, nucleic acids or small molecule 
second messengers. These latter interaction domains play a critical role in the 
selective activation of signaling pathways, through their ability to recruit target 
proteins to activated receptors, and to regulate the subsequent formation of signaling 
complexes at appropriate subcellular locations. Such interaction domains may control 
not only the specificity of signal transduction, but also the kinetics with which cells 
respond to external and intrinsic cues, and can therefore give rise to complex cellular 
behaviors. 
An intriguing challenge is to understand how interaction domains cooperate to 
establish the complex signaling networks, controlling events as fundamental and as 
complex as cell development, maintenance of homeostasis and immune system 
function. The cellular life-cycle is actually governed by of one of the most important 
regulated processes: the apoptotic cascade pathway [1]. 
Apoptosis is a conserved, gene-directed mechanism for the elimination of 
unnecessary or dangerous cells and is essential for maintaining a fine balance an for 
the well-being of a multicellular organism [2].  
Dysregulation in apoptosis mechanisms may contribute to a variety of human 
diseases such as autoimmune syndromes, lymphomas and solid tumors. 
The apoptosis result in a complex cascade of events and signaling pathways 
involving a large variety of receptors and proteinaceous factors, such as a family of 
proteins belonging to the so called “Death Domain” superfamily, composed of the 
“death domain” (DD), the “death effector domain” (DED) and the “caspase 
recruitment domain” (CARD) proteins. These proteins share a common involvement 
in signalling events regulating apoptosis by mediating the interactions necessary for 
transducing a “death signal” in a vital process of normal cell development and 
maintenance of homeostasis [3].  
 
Homotypic interactions between proteins containing CARDs, DEDs or DDs have 
been found in divergent signalling pathways resulting in caspase activation and 
apoptosis. Several CARD-containing caspase, indeed, have been implicated in 
proteolytic processing of cytokines involved in the inflammatory response. The 
caspase recruitment domain (CARD) is a protein module that participates in 
apoptosis signaling through protein-protein interactions and several CARD proteins 
have been found to assemble into discrete signaling complexes [4]. 
Proteins containing CARD domains can be divided in subfamilies based on their 
overall domain structures: NBD-CARDs, coiled-coiled CARDs, bipartite-CARDs and 
CARD-only proteins. 
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The NBD-CARDs contain a nucleotide-binding domain in addition to CARD segment 
that acts as an oligomerisation surface. The coiled-coiled CARD proteins are 
structurally similar to the NBD-CARDs but the central NBD is replaced by a coiled-
coil motif acting as an oligomerisation surface. The bipartite-CARDs contain a CARD 
domain and one other motif like a kinase domain or a protease domain. The CARD-
only proteins may act as positive or negative regulators of the multi-domain CARDs 
by regulating the recruitment between proteins [5]. 
All of the proteins belonging to bipartite-CARD subfamily appear to recruit coiled-
coiled CARD via CARD-CARD interactions and they often promote the inducible 
transcription factor NF-kB activation, leading to apoptosis-related defects. 
 
Lymphocyte activation is trigged by a stimulation of antigen receptors on the surface 
of T or B lymphocytes inducing a series of signal transduction cascades leading to 
activation of multiple transcription factors, including NF-kB. 
NF-kB (nuclear factor-kB) is found in essentially all cell types. It is a dimeric 
transcription factor structurally and functionally related to the family of DNA-binding 
proteins that recognize a common sequence motif [6]. The signaling pathway leading 
to the activation of this transcription factor has been largely investigated. However, 
how factors involved in the signaling interact with each other is still a debatable issue. 
Since many nodal signal molecules in this pathway relay more than one of the 
upstream signals to their downstream targets, it has been speculated that the 
transmission of signals involves a network, rather than a linear sequence in the 
activation of NF-kB. In the cytoplasm, NF-kB is normally inhibited by IkB.  The 
activation of NF-kB is dependent on the phosphorylation and subsequent 
degradation of IkB proteins [7]. IkB degradation occurs after its inducible 
phosphorylation, which results in ubiquitination and degradation by the proteasome 
[8]. The free and activated NF-kB can then translocate to the nucleus where it 
regulates gene transcription. 
 
The inhibition of NF-kB/IkB kinase complex is responsible for the phosphorylation of 
molecules normally retaining NF-kB in an inactive state in the cytoplasm. In most 
cells, NF-kB activation protects from apoptosis, through induction of survival genes, 
although under certain conditions and in certain cell types it may also induce 
apoptosis [9, 10]. 
The antigen receptor-mediated signal to activate NF-kB of T and B cells is related to 
the protein Bcl10. The pathway by which this protein activates NF-kB is still unclear; 
however, several factors have been shown to participate in this biological process. 
Recent studies have identified a signalling complex involving Bcl10 and other two 
proteins: CARMA1, and MALT1 [11]. Such a complex has a key role in antigen-
receptor-mediated activation of the NF-kB linking antigen receptors on B and T cells 
to the IkB kinase complex and is crucial for the activation and proliferation of mature 
B and T cells. Deletion of any one of these proteins impairs the ability of antigen 
receptors to activate NF-kB but appears not to affect other pathways [12]. 
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Figure 2.I.1: CARMA1, Bcl10 and MALT1 complex scheme 
 
In T lymphocytes, Bcl10 normally resides in the cytoplasm and specifically relays 
antigen-receptor–mediated signals to activate nuclear factor NF-kB [13]. 
Bcl10 nuclear expression was found to be more closely associated with the genetic 
aberration and advanced tumor stages, in gastric MALT lymphoma [14]. Mucosa-
associated lymphoid tissue (MALT) lymphomas are the most common type of B-cell 
human lymphomas virtually affecting every organ in the human body but the majority 
occur in the stomach. 
The pathogenesis of MALT lymphomas is specifically associated with, at least 3 
independent chromosomal translocations. Two of them, t(1;14)(q22;q32) and 
t(14;18)(q32;q21), result in the upregulation of bcl10 gene and its related factor 
MALT1, leading to a mechanism of overexpression of the gene product and, 
consequently, to cellular oncogenesis [15]. 
In particular, molecular cloning of the breakpoint t(1;14)(p22;q32) has identified the 
translocation of bcl10. This translocation juxtaposes bcl10 gene of chromosome 1 to 
the immunoglobulin heavy chain gene locus of chromosome 14, resulting in 
overexpression of Bcl10 protein in the nuclei and cytoplasm, in contrast to the weak 
cytoplasmic expression of Bcl10 in normal germinal center B. 
Oncogene activation is often related to translocations, in which rearrangements often 
involve the immunoglobulin heavy chain IgH gene. Translocations into the 
immunoglobulin loci result in dysregulation of the uncoming gene, and may be due to 
transcriptional factors at these sites or mutation events within these regions [16].  
The overexpressed Bcl10 in MALT lymphomas contains a variety of mutations, 
resulting in protein truncations and plays a critical role in antigen receptor–mediated 
lymphocyte proliferation and signaling to the nuclear factor NF-κB, controlling the 
expression of genes critical for cell survival, proliferation, and immune responses [17, 
18]. Bcl10 pathway is still to be clarified but several studies have been focused on its 
interactions with other protein partners mediated by its CARD domain [19]. 
In normal B-cells, in response to antigen-receptor signalling, Bcl10 oligomerizes, via 
its N-terminal CARD, and interacts with MALT1. Recent studies have shown that 
Bcl10 and MALT1 mediate NF-κB activation, by facilitating polyubiquitination of 
subunit of the IkB kinase complex. MALT1, is a member of the conserved superfamily 
of caspase-like proteins. Although Bcl10 and MALT1 are two independent targets of 
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chromosomal translocation in MALT lymphomas, they form a tight complex in vitro 
[20, 21].  
CARMA1 binds Bcl10 and induces its phosphorylation and translocation from the 
cytoplasm into perinuclear structures [22, 23]. Bcl10 phosphorylation is correlated 
with its ability to activate NF-kB, suggesting that this modification is required for NF-
kB activation [4]. CARMA1 is a member of the membrane-associated guanylate 
kinase (MAGUK) family of scaffold proteins that assemble signal-transduction 
complexes by binding to both transmembrane and intracellular signalling molecules 
at sites of cell–cell contact [24].  
Bcl10 CARD interacts with both MALT1 caspase-like domain and CARMA1 which is 
classified as a coiled-coiled CARD protein (figure 2.I.2) [11]. 
 
 
 
 
Figure 2.I.2: Structure scheme of CARMA1, Bcl10 and MALT1. CARMA1 and Bcl10 possess a CARD 
domain and their interaction occurs via CARD/CARD. MALT1 possess a “caspase-like” domain which 
binds the other CARDs 
 
Bcl10 has a bipartite structure consisting of an N-terminal CARD and a C-terminal 
domain that is rich in serine-threonine residues. 
Although there are no structures available for Bcl10 CARD domain, other CARDs 
have been studied by NMR and X-Ray crystallography [25]. 
Crystal and solution NMR structure has been reported for other proteins related to 
apoptosis such as RAIDD and Apaf1, a multi-domain protein with an N-terminal NBD-
CARD and C-terminal repeats, responsible for recruitment of caspase9 via CARD-
CARD interactions with consequent activation of the apoptosis cascade [26, 27].  
 
 
a)          b)  
 
Figure 2.I.3: a) Crystal structure of the protein Apaf1 CARD domain in complex with caspase 9 CARD 
domain.The CARD-CARD interaction involves significant charge-charge interactions between the 
helices 2 and 3 of Apaf1 and the helices 1 and 4 of procaspase9. b) CARD domain model for Bcl-xL. 
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All CARDs possess a remarkably similar secondary structure and often a discrete 
sequence identity. They are 10-15 kDa domains located at the N-terminus and 
consisting in antiparallel six helical bundle in the Greek key topology that form highly 
specific homophilic interactions between signaling partners [28].  
 
A recent study [29] demonstrate that Bcl10 may also undergo homo-dimerization via 
CARD-CARD interactions. This oligomerization event is responsible of Bcl10 
assembly in cytoplasmic filaments. The evidences provided in this study show that 
filaments serve as scaffold for recruitment of NF-κB-activating signal transduction. 
Generation of filaments seems to be essential for the activation of a signaling 
cascade leading to cellular apoptosis and inhibition of filament formation prevents cell 
death. These observations make the investigation on CARD-CARD self-association 
an intriguing issue. 
 
In order to provide a better understanding of Bcl10 CARD self-association 
mechanism, the first part of this thesis work is focused on dimerization studies based 
on the structural behaviour of the Bcl10 CARD domain in solution. 
Further evidences of CARD-CARD association are provided and the specific regions 
involved in this homophilic interactions have been investigated to clarify how 
alterations, in these interactions, leads to alterations in apoptosis signals and, 
consequently, to oncogenesis. 
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2.I.2  Methods 
 
 
Protocol for CARD domain cloning, expression and purification 
 
CARD domain (produced by “Dipartimento di Biologia Molecolare, II Policlinico, 
Napoli) was obtained as mutant of the wild-type human Bcl10 CARD. 
The wild-type sequence is: 
 
MEPTAPSLTEEDLTEVKKDALENLRVYLCEKIIAERHFDHLRAKKILSREDTEEISCRT
SSRKRAGKLLDYLQENPKGLDTLVESIRREKTQNFLIQKITDEVLKLR 
 
Two cysteine residues (underlined in bold) of this sequence were mutated in serine 
by site-directed mutagenesis of the wild-type gene (Quik Change Site-Directed 
Mutagenesis Kit commercially available from Stratagene), and, the mutated 
sequence, was cloned in pET 28 vector to obtain a fusion-(His)6 protein with a ∆-link 
of 36 residues (poly-histidine tag included). The expression was carried out in BL21 
(DE3) E. coli strain by growing the cultures at 37°C and inducing with 1 mM IPTG 
after 3 hours. The cultures were grown overnight at 37°C and the pellets were lysed 
in PBS buffer 8 M urea. The purification was performed by affinity chromatography by 
adding the lysate to a Ni2+-chelated resin column, equilibrated in 100 mM phosphate , 
10 mM TRIS-HCl buffer pH= 8.0 and 8 M urea. The protein was eluted with a 
gradient of pH from pH=8.0 to pH= 4.5. The final step of purification was performed 
by gel filtration on a Sephadex G150 column in buffer 50 mM TRIS, pH=4.0, dialyzed 
against buffer sodium acetate 100 mM pH= 4.0, lyophilized and stored at 4°C. 
The aminoacidic sequence expressed is the following: 
 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFMEPTAPSLTEEDLTEVK
KDALENLRVYLSEKIIAERHFDHLRAKKILSREDTEEISSRTSSRKRAGKLLDYLQENP
KGLDTLVESIRREKTQNFLIQKITDEVLKLR 
 
where the two mutations are underlined in bold and the ∆-link with the His-tag is in 
bold characters. The following studies, reported in this thesis, are referred to this 
Bcl10 CARD mutant sequence even though, the domain cited is simply named as 
CARD. 
 
Protocol for biotinilation: 
 
A protein is typically labelled with the water-soluble vitamin biotin to tag it for later 
recovery or for detection with biotin-binding proteins, such as avidin or streptavidin. 
The reagent used, NHS-LC-biotin has an N-hydroxysuccinimide (NHS) ester group to 
increase reactivity with primary amines and long-chain (LC) spacer arm to extend the 
biotin from the protein surface, improving binding of subsequent reagents. 
 
 
 
Figure 2.I.4: NHS-LC-Biotin 
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1 mg/mL purified CARD was dissolved in the coupling buffer (Sigma). NHS-LC-biotin 
solution 2 mg/mL (freshly prepared by dissolving biotin in EtOH to 2 mg/mL) was 
added to the solution. The mixture was incubated for 1 hour on ice, occasionally 
mixing. After incubation, 1 volume of 50 mM glycine solution (in coupling buffer) was 
added to bind unreacted biotin. Then glycine was removed to free biotin by dialysing 
for 48 hours against coupling buffer. The biotinilated CARD solution was sterilized by 
passing the solution through a 0.22-µm filter and stored at 4°C.  
The yield of CARD biotinilated product is not the same for each preparation. For this 
reason the OD was measured before use for each new preparation of labeled CARD. 
 
 
 
 
 
Figure 2.I.5: Acrylamide SDS-PAGE gel (15%) in reducing conditions. The gel shows the CARD 
sample before and after biotinilation. 
 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Biotinilated CARD was used as biotin-labelled protein in ELISA assays to test the 
self-association properties of this domain by using the biotin-streptavidin detection 
system. 
 
Protocol  
 
The ELISA system uses polystyrene plates (Falcon) for protein binding. The plates 
are treated with UV to obtain sterile conditions and to enhance binding properties. 
The binding occurs between the protein sample and the polystyrene surface. 
 
Lyophilized unlabelled CARD was dissolved in buffer sodium acetate 50 mM pH= 4.0 
to obtain three different concentrations: 1.0 µg/mL,  0.50 µg/mL, 0.10 µg/mL. 
This sample is insoluble at pH values between 4 and 7.  
Each solution was spinned at 12 kRpms for 20 minutes, to avoid any precipitate. 
 
Coating: binding of the unlabelled protein to the bottom of each well of the plate. 
100 µL unlabelled CARD solution was placed in each well. The plate was incubated 
at 37°C for 3 hours to allow complete binding. 
Washing: the wells were washed 3-5 times with PBS buffer 0.04% Tween-20 to 
remove all the molecules which have not been specifically bound to the plate. 
Biotinilated 
CARD 
Unlabelled CARD 
25 kDa 
15 kDa 
 20
Blocking: the remaining sites for protein binding on the plate must be saturated by 
incubating with blocking PBS buffer containing Bovine Serum Albumin (BSA) to avoid 
non-specific bindings. The wells were filled to the top with 250 µL  BSA 1% (Sigma) 
in PBS buffer 0.04% Tween-20. Then, the plate was incubated for 2 hours at 37°C. 
Washing: wells were washed twice with PBS buffer 0.04% Tween-20. 
Second coating: application of the labelled (biotinilated) CARD to the wells (100 µL). 
Increasing concentrations biotinilated CARD (6.25 µg/mL, 12.5 µg/mL, 25.0 µg/mL, 
and 50.0 µg/mL) in buffer sodium acetate 50 mM pH= 4.0) were applied to the wells 
containing unlabelled CARD. The plate was incubated for 1 hour at 37° C. 
Washing: the plate was washed four times with PBS buffer 0.04% Tween-20. 
Signal amplification with biotin-streptavidine method: the wells were filled up 
with 100 µL streptavidine conjugated with horseradish peroxidase (HRP) enzyme 
(solution 1mg/mL in buffer PBS-sodium phosphate 1X, 137 mM NaCl, KCl 27 mM 
Na2HPO4,10 mM KH2PO4, 2 mM, pH=7.4 provided by Sigma) and incubated for 1 
hour at 37°C and then washed 3 times with PBS washing buffer. 
Detection: the wells were filled up with 100 µL detection buffer (citrate-phosphate 50 
mM pH=5.0; H2O2  [0,4mg/ml]; ortophenyldiamine (OPD)  [0,4mg/ml] (prepared by 
using the Sigma FAST OPD tablet sets KIT). This buffer should be freshly prepared 
before use. The plate was incubated at 37°C for 1 hour to reveal the binding of 
biotinilated CARD to the unlabelled CARD. The substrate is sensible to the light, so 
the plate was covered with aluminium paper to avoid any alteration in the response. 
OPD reaction produces colorimetric effect: the reaction solution changes from 
colorless to yellow and this changing can be quantitatively detected by measuring the 
intensity of the absorbance at 490 nm. The observed intensity is directly related to 
the amount of protein bound. This reaction went on till sulphuric acid 2.5 M was 
added (50 µL in each well). 
The CARD/CARD binding properties were evidenced in this preliminary assay. The 
results are reported in the section 2.I.3. 
 
Proteolytic Digestion 
Proteins are specifically cleaved into small fragments to facilitate their identification. 
Specific cleavage can be achieved by trypsin which specifically hydrolyzes peptide 
bonds at the carboxyl side of lysine (Lys, K) and arginine (Arg, R) residues. Tryptic 
digestion is part of the standard protein analysis by mass spectrometry. 
Trypsin is a pancreatic serine protease (Mr ~24 kDa). The aspartate residue in the 
binding site enables trypsin to form a salt bridge with positively charged residues (Lys 
and Arg side-chains) of the substrate, thus enabling the cleavage reaction to occur. 
Trypsin can undergo autolysis and lose activity. A chemically modified trypsin which 
does not undergo autolysis and retains high enzymatic activity is commercially 
available and has been used for this studies’ purposes.  
Protocol for tryptic digestion 
 
CARD was dissolved in a solution buffer TRIS 50 mM, pH=7.5, CaCl2 20 mM and 
10% acetonitrile was added to enhance the solubility. 0.1 µg/µL solution of trypsin 
(TPCK-treated trypsin from Sigma-Aldrich, Milan, Italy) was prepared using the same 
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buffer. CARD and trypsin solutions were mixed together in 100:1 (w:w) ratio. The 
reaction mix was incubated overnight at 37°C.  
 
 
Selection of tryptic CARD fragments 
 
In order to identify the fragments produced from the hydrolysis with trypsin, and to 
test them in a competitive ELISA assay, the digested mix was passed through a 
preparative RP-HPLC (Shimadzu HPLC equipped with a C18 Jupiter column 
250x22mm ID column (15 µm, 300 Å) applying a linear gradient of acetonitrile in 
0.1% TFA from 5% to 70% in 50 min. 
 
 
 
 
 
Figure 2.I.6: Preparative RP-HPLC chromatogram of digested CARD. The fraction were collected 
each 10 min. and named as 1F to 11 F. 
 
Peaks were collected each 10 minutes in Falcon tubes. The fractions, collected from 
the tryptic digestion and named from 1F to 11F, were tested by competitive ELISA 
assay against the whole CARD. 
 
Protocol for competitive ELISA assay CARD/CARD digested fractions: 
 
Coating: binding of the unlabelled CARD 12.5 µg/mL (this is the unlabelled CARD 
concentration previously described for pre-saturation conditions). The plate was 
incubated at 37°C for 3 hours to allow complete binding. 
Washing: the wells were washed 3-5 times with PBS buffer 0.04% Tween-20 to 
remove all the molecules which have not been specifically bound to the plate. 
Blocking: The wells were filled to the top with 250 µL in  BSA 1% (Sigma) in PBS 
buffer 0.04% Tween-20. Then, the plate has been incubated for 2 hours at 37°C. 
Washing: wells were washed twice with PBS buffer 0.04% Tween-20. 
Competition: the competition mix is composed of tryptic fragment and biotinilated 
CARD in two different ratio: mix 1:1 (w/w) and 10:1 (w/w) in sodium acetate 50 mM 
pH=4.0. The labelled CARD concentration was chosen, from the previous ELISA test, 
before the saturation point value and, with this aim, a concentration of 0.5 µg/mL of 
biotinilated CARD was used. The two reaction mixes were pre-incubated at 37°C for 
45 min. To allow the fragments to better interact with labelled CARD. 
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Second coating: application of the biotinilated CARD/tryptic fragments mix to the 
wells (100 µL). The plate was incubated for 1 hour at 37° C. 
Washing: the plate was washed four times with PBS buffer 0.04% Tween-20. 
Signal amplification with biotin-streptavidine method: 
The wells were filled up with 100 µL streptavidine conjugated with horseradish 
peroxidase (HRP) enzyme (solution 1mg/mL in buffer PBS-sodium phosphate 1X, 
137 mM NaCl, KCl 27 mM Na2HPO4,10 mM KH2PO4, 2 mM, pH=7.4, provided by 
Sigma) and incubated for 1 hour at 37°C and then washed 3 times with PBS washing 
buffer. 
Detection: the wells were filled up with 100 µL detection buffer (citrate-phosphate 50 
mM pH=5.0; H2O2 [0,4mg/ml]; ortophenyldiamine (OPD) [0,4mg/ml] prepared by 
using the Sigma FAST OPD tablet sets KIT). The plate was incubated at 37°C for 1 
hour. The reaction was detected by measuring the absorbance at 490 nm. 
From this preliminary assay 3 fractions were selected: 3F, 8F and 9F (ELISA assay 
results are shown and discussed in section 2.I.3.2. The fraction 11F shows very low 
binding properties. 
 
 
LC-MS characterization of digested CARD: 
 
The CARD sequence: 
 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFMEPTAPSLTEEDLTEVK
KDALENLRVYLSEKIIAERHFDHLRAKKILSREDTEEISSRTSSRKRAGKLLDYLQENP
KGLDTLVESIRREKTQNFLIQKITDEVLKLR 
 
Number of amino acids: 143,  molecular weight: 16328.4 
 
with  the two cysteines, mutated in serine residues and the ∆-link, including the His-
tag was employed for all the experiments but the numbering reported for the 
identified sequences is referred to the “wild-type”, without the ∆-linker. For the 
identification of the tryptic fragments the program MS-Digest for trypsin digestion 
cleavage was used on the web page http://www.expasy.org/tools. The following 
CARD fragments were identified by LC-MS. Near the fragments sequence the 
corresponding fraction number of the digestion mix is reported.  
 
 
CARD [32-36]: IIAER                                              (3F) 
CARD [50-62]: EDTEEISSRTSSR                         (3F) 
CARD [26-49]: VYLSEKIIAERHFDHLRAKKILSR  (3F) 
CARD [26-31]: VYLSEK                                          (4F) 
CARD [78-87]: GLDTLVESIR                                 (5F) 
CARD [78-88]: GLDTLVESIRR                               (5F) 
CARD [37-42]: HFDHLR                                         (6F) 
CARD [99-105]: ITDEVLK                                       (6F) 
CARD [19-25]: DALENLR                                               (7F) 
CARD [91-98]: TQNFLIQK                                      (8F) 
CARD [89-98]: EKTQNFLIQK                                 (8F) 
CARD [68-77]: LLDYLQENPK                                (9F) 
CARD [46-58]: ILSREDTEEISSR                           (11F) 
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LC-MS analyses were performed by using a LCQ DCA XP Ion Trap mass 
spectrometer, equipped with a narrow bore, C18 BioBasic 50x2 mm ID column 
(Thermo Electron, Milan, Italy) and applying a gradient of solvent B (0.05% TFA in 
CH3CN) on solvent A (0.08% TFA in H2O) from 30 % to 70 % (v/v). 5 µL of each 
sample (0.1 mg/mL) were injected for this analysis. The global LC-MS profile and the 
corresponding identified fragments and their discussion are reported in figure 2.I.9 in 
section 2.I.3.2. 
 
 
CARD peptides synthesis 
 
The following fragments, previously selected from ELISA assay as CARD binding 
regions, were obtained by Solid-phase peptide synthesis using Fmoc synthesis 
strategy. The first fragment, together with its related longer sequence peptides: 
CARD [78-98] and CARD [68-98], are belonging to the fraction 8F, collected from the 
tryptic digestion. The fragment CARD [68-77] is belonging to the collected fraction 9F 
and CARD [26-49] is belonging to the fraction 3F. 
 
Sequences: 
 
CARD [91-98]: TQNFLIQK                    
CARD [78-98]: GLDTLVESIRREKTQNFLIQK 
CARD [68-98]: LLDYLQENPKGLDTLVESIRREKTQNFLIQK 
 
CARD [68-77]: LLDYLQENPK               
CARD [26-49]: VYLSEKIIAERHFDHLRAKKILSR    
 
The first three sequences were tested by ELISA competitive assay to determine their 
behaviour in competing with the whole CARD domain to bind the CARD itself (section 
2.I.3.2). The other sequences were synthetized but so far never tested. Further 
experiments are in progress. 
 
Protocol 
 
Peptides N-terminal acetilated and C-terminal amidated, were synthesized in batch 
by standard Fmoc chemistry protocol on Rink-amide MBHA resins. Acylations were 
carried out in 50% DCM/DMF for 15 min using PyBOP/DIEA (1:2) as activating 
agents (without preactivation) with a four-fold amino acid excess. Fmoc removal was 
achieved by 30% piperidine/DMF treatment for 10 min. After peptide assembling, 
acetylation was carried out by treatment with a 1 M solution of acetic anhydride in 
DMF containing 5% DIEA. Cleavage from the resin was achieved by treatment with a 
trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water (90:5.0:5.0 v/v/v) mixture for 
90 min at room temperature. Then, peptides were precipitated in ether, dissolved in 
water/acetonitrile (1:1 v/v) mixture, lyophilized, and purified. Chemical and organic 
reagents were from Sigma-Aldrich (Milan, Italy). N-α-Fmoc protected amino acids 
and the activating agents were purchased from Inbios (Pozzuoli, Italy). Resins for 
peptide synthesis were from Novabiochem (Laüfelfingen, CH). 
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Protocol for CARD peptides purification 
 
Peptides purification was carried out by RP-HPLC using a Shimadzu purifier 
equipped with a  C18 Jupiter 250x22mm ID column (15 µm, 300 Å) applying a linear 
gradient of acetonitrile in 0.1% TFA from 10% to 60% in 50 min. Peptide purity and 
integrity were confirmed by RP-HPLC analysis using analytical columns (Jupiter C18, 
250 x 4.6 mm ID,15 µm, 300 Å) and LC-MS on a LCQ DCA XP Ion Trap mass 
spectrometer (Thermo Electron, Milan, Italy). All solvents were reagent grade. HPLC 
chemicals were purchased from Lab-Scan (Dublin, Ireland), while other Columns 
(C18) for peptides purification and characterization were from Phenomenex 
(Torrance, CA). 
Circular Dichroism Spectroscopy of Proteins 
 
Different types of protein secondary structures (helices, sheets, turns and coils) give 
rise to different CD spectra. The wavelengths of light that are most useful for 
examining the structures of proteins and peptides are in the ultraviolet (UV) ranges 
(from 160 to 300 nm) because these are the regions of the electronic transitions of 
the peptide backbone and side chains in proteins.  
Table 2.I.1: Far UV-CD transitions for soluble proteins 
α-helix positive π -> π * 190-195 nm 60,000 to 80,000 deg cm2 dmol-1 
  negative π -> π * 208  -36,000 ± 3,000 
  negative n-> π * 222  -36,000 ± 3,000 
β-sheet positive π -> π * 195 - 200 30,000 to 50,000 
  negative n-> π * 215 - 220  -10,000 to -20,000 
random negative π -> π * ca. 200 -20,000 
  positive n-> π * 220  small 
 
CD spectroscopy has been used to monitor: 1) secondary structure, 2) 
conformational changes, 3) environmental effects, 4) protein folding and 
denaturation, and 5) dynamics and can be used to analyze a number of  proteins 
from which interesting candidates can be selected for more detailed structural 
analysis like NMR or X-ray crystallography.Monitoring θ222nm of a protein as a 
function of temperature or chemical denaturant yields information about protein 
stability. The absorption should be less than 1.0 (usually < 0.3) for cell pathlengths of 
0.05 to 1.00 cm in order to maintain reasonable signal-to-noise ratios and accurate 
CD measurements. Protein concentration is typically 1 mg/mL. Buffers are typically 
10 mM phosphate with low salt if any. 
Thermal stability is assessed using CD by following changes in the spectrum with 
increasing temperature. In some cases the entire spectrum in the far-UV CD region 
can be followed at a number of temperatures. Alternatively, a single wavelength can 
be chosen which monitors some specific feature of the protein structure, and the 
signal at that wavelength is then recorded continuously as the temperature is raised. 
CD is often used to assess the degree to which solution pH, buffers, and additives 
such as sugars, amino acids or salts alter the thermal stability. Many proteins 
 25
aggregate or precipitate quickly after they are unfolded ("melted"), making unfolding 
irreversible. The reversibility of the unfolding reaction can be assessed by cooling the 
sample and then heating again to see if the unfolding reaction is duplicated. Only if 
the melting is fully reversible, the melting temperature is directly related to 
conformational stability, and the thermodynamics of protein folding can be extracted 
from the data. The fact that thermal unfolding can generally be measured by CD at 
much lower concentrations than by DSC increases the probability of reversible 
reactions and of thermodynamically interpretable data. Fitting the data also allows a 
more reproducible measurement of the onset of unfolding, a temperature which is 
often more relevant for formulation and shelf-life considerations than the midpoint. If 
the protein precipitates or aggregates as it is unfolded, the melting reaction will be 
irreversible, and the melting temperature will reflect the kinetics of aggregation and 
the solubility of the unfolded form of the molecule as well as the intrinsic 
conformational stability. The cooperativity of the unfolding reaction is measured 
qualitatively by the width and shape of the unfolding transition. A highly cooperative 
unfolding reaction indicates that the protein existed initially as a compact, well-folded 
structure, while a very gradual, non-cooperative melting reaction indicates that the 
protein existed initially as a very flexible, partially unfolded protein or as a 
heterogeneous population of folded structures.   
 
Protocol for CARD peptides characterization by Circular Dichroism 
 
The following synthetic peptides were characterized by far-UV circular dichroism: 
 
CARD [68-98]: LLDYLQENPKGLDTLVESIRREKTQNFLIQK 
CARD [78-98]: GLDTLVESIRREKTQNFLIQK 
 
Each peptide was characterized in buffer phosphate 10 mM at two different pH 
values: pH=7.5 and pH=4.5 by using a Jasco J-810 spectropolarimeter in 1.0 cm 
quarz cuvettes. CD spectra are reported in molar ellipticity [θ] in section 2.I.3.2. 
 
Parameters: 
 
Peptide concentration: 10 µM, wavelength range: 190 nm - 260 nm, scan Speed: 20 
nm/min, band widht: 2.0 nm, resolution: 1.0 nm, sensitivity: 50 mdeg, response: 16 s, 
accumulation: 3 
 
Protocol for Circular Dichroism characterization of CARD domain 
 
Bcl10 CARD far-UV CD spectra for dimerization study were performed in sodium 
acetate 5 mM buffer solution at pH=4.5 and at room temperature on a Jasco J-810 
spectropolarimeter. A set of 7 different pathlenght cuvettes was used (from 0.01 cm 
to 5 cm). CD spectra , in molar ellipticity [θ], and the used CARD concentrations, are 
reported in section 2.I.3.1. 
 
Parameters: 
 
Wavelength range: 195 nm - 260 nm, scan Speed: 20 nm/min, band widht: 2.0 nm, 
resolution: 1.0 nm, sensitivity: 50 mdeg, response: 16 s, accumulation: 3 
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Nuclear Magnetic Resonance (NMR)  
 
NMR methods are used to determine the primary, secondary and tertiary structure of 
peptides and proteins in solution. One and two-dimensional (1D and 2D) NMR 
experiments are used to assign the chemical shifts of all peptide protons. The set of 
distance and angular constraints are input into molecular modeling programs to 
calculate a tertiary structure if a unique fold exists. Typical sample concentrations for 
structure determination are 1 to 2 mM in a 750 microliter 5 mm sample tube for the 
600 MHz instrument. 
The H-α chemical shift of amino acids in a polypeptide or protein is a widely used 
indicator of secondary structure. The ”secondary structure shift'' is defined as the 
difference between the observed chemical shift and the appropriate random coil 
value. There is a relationship between shift and secondary structure context, 
demonstrating downfield chemical shifts in beta-sheets and upfield shifts in alpha-
helices and turns. The origin of these observed chemical shift changes remains a 
matter of some debate. A large number of studies [30, 31], show that H-α chemical 
shift is largely determined by neighbouring residue effects and local backbone 
restriction. Nuclear Magnetic Resonance provides a powerful method for 
determination of peptides and proteins structures. It is the only technique that can 
provide detailed information on the exact three-dimensional structure of biological 
molecules in solution. NMR measurement, generate information about spatial 
proximity of protons in a molecule. These spatial information can be used to generate 
models of peptides or polypeptides chains, giving rise to structures comparable with 
defined 3-Dimensional structures in solution. It is generally observed that such 
models are very close to the structure determined by X-Ray crystallography in the 
crystalline state. 
 
Protocol for NMR experiments 
 
In order to provide the optimal experimental conditions (peptide concentration, pH 
and temperature), several preliminary experiments were performed on the synthetic 
fragment CARD[78-98]. NMR experiments were recorded on a Varian Inova 600 
spectrometer at temperature of 25°C, located in “Istituto di Biostrutture e Bioimmgini” 
of CNR, Naples. All the spectra were processed and analyzed with the software 
MestreC (Mestrelab Research Santiago de Compostela a Coruna, Spain). 
CARD[78-98] assayed concentrations in NMR preliminary experiments: 1.0 mM 
peptide neat H2O (10 % D2O; 600 µL) at 25°C pH=3.5, 0.60 mM peptide neat H2O 
(10 % D2O; 600 µL) at 298 K pH=3.5, 0.30 mM peptide neat H2O (10 % D2O; 600 µL) 
at 25°C, pH=3.5, 0.10 mM peptide neat H2O (10 % D2O; 600 µL) at 25°C pH=3.5. 
In these experimental conditions 1D spectra showed changing of intensity and 
multiplicity of signals. In the second set of experiments, the following conditions were 
used: 0.1 mM concentration peptide H2O (10% D2O; 600 µL) 5.0 mM Na acetate 
buffer pH=5.5. These conditions were chosen as the best for spectra acquirements. 
Spectra and discussion in section 2.I.3.2. 
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2.I.3  Results and discussion 
 
 
2.I.3.1   Structural and dimerization properties of Bcl 10 CARD  
 
The “Caspase-recruitment domain” (CARD) is a protein-binding module that 
mediates the assembly of CARD-containing proteins into apoptosis cascade 
signaling. The inhibition of these interactions between the involved proteins, such as 
Bcl10, causes pathogenesis. CARD-mediated homophilic interactions between Bcl10 
CARDs cause Bcl10 multimerization and filaments formation. This organization is 
essential for the NF-κB activation and apoptosis signaling activation. 
These studies aim to investigate into CARD domains self-association and to identify 
the specific regions involved. A physical-chemical approach has been used to 
describe CARD monomer-dimer equilibrium and to calculate the dissociation 
constant for CARD dimer formation. 
 
Binding interactions between proteins are non-covalent, so they are weak and 
usually reversible and binding is stabilized by the same nonbonded interactions that 
stabilize folded proteins, such as the hydrophobic effect, van der Waal’s contacts, 
hydrogen bonds, and salt bridges. Binding reactions can be described by simple 
chemical equilibria. For the association of a molecule A with a molecule M, the 
equilibrium expression is given by the equation: 
 
M + A  MA   
 
Kd = [M][A]/ [MA] 
 
Where Kd is the dissociation constant which is the reciprocal of the corresponding 
association constant Ka. Kd is usually expressed in units of concentration (M), 
assuming that the activities of the equilibrium components are corresponding to their 
concentrations. 
If a protein, with a specific domain, binds to another protein or self-associate to form 
a dimer or an oligomer, the interactions usually involve modification of secondary 
structure elements in the protein folding. In this study the homodimerization, 
occurring between two identical CARD domains in solution, has been considered and 
the dissociation constant for its dimer has been calculated. Furthermore it has been 
calculated the percentage of CARD in monomeric form in dependence of the 
concentration. 
This study starts from the consideration that the CARD domain can be present in 
solution in two forms: monomer (M) and dimer (D) and between the two forms the 
following equilibrium is considered: 
 
2M  D            (1) 
 
The dissociation can be described with a constant Kd. 
 
Kd = [M] x [M]/ [D]                                                                                               (2) 
 28
 
The total protein concentration can be identified as x because is the only variable 
parameter considered in the experiment. It can be obtained by adding monomer and 
dimer concentration and by expressing the dimer concentration as the monomer 
multiplied for two: 
 
 x= [M]+2•[D]  (3) 
 
If α is the protein fraction present in monomeric form on the total concentration of 
the CARD domain:    α = [M]
x
 
 
 
      (4) 
 
transferring in the first equation D and M it becomes: 
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Solving the equation it is possible to obtain the expression: 
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The experiments here considered are expressed in molar residue ellipticity, [θ]. 
This parameter can be written as y and is corresponding to the hypothetical value 
observed when the monomeric form is the only one present in solution (a), multiplied 
for the monomeric fraction (α) and adding the value that would be observed if only 
dimer is present (b) multiplied for the dimer fraction (1-α).  
The resulting equation can be written as: 
 
)1( αα −•+•= bay                                                                                         (7) 
 
Writing α value obtained combining the equation (4) with the equation (5) the global 
expression can be written as: 
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1−α = 2[D]
x
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Circular Dichroism Experiments  
 
CARD domain belonging to the human protein Bcl10 with 2 cysteines mutated in 
serines was characterized in solution by far-UV circular dichroism to investigate the 
conformational behaviour of the domain. The behaviour of a protein in specific 
conditions of pH and temperature, together with the dependence of the spectroscopic 
parameters from the concentration can be used to study the tendency of the protein 
to adopt monomeric or oligomeric forms. 
Far UV-CD spectra were acquired for Bcl10 CARD in sodium acetate 5 mM buffer 
solution at pH= 4.5 and at room temperature. In these conditions the domain shows a 
typical α-helical folding. The spectrum reported in the figure below shows one 
negative band centered at 208 nm with a shoulder at 222 nm and a positive band at 
196 nm wavelength. These values are typical for α-helical structures. 
 
 
 
 
 
 
 
Figure 2.I.7: Bcl10 CARD far-UV CD spectrum in buffer sodium acetate 5 mM pH=4.5. The spectrum 
is a typical α-helical spectrum and shows a positive band at 196 nm wavelength and two negative 
bands at 208 nm and 222 nm. 
 
In order to study and to verify the self-association between CARD domains it is 
possible to monitor a change in the spectroscopic properties of the protein. If there is 
a linear dependence between the chosen spectroscopic parameter and the protein 
concentration, it might be that there no self-association.  
For this study it has been chosen the molecular ellipticity measured by far-UV circular 
dichroism, but any other spectroscopic parameter dependent on the sample 
concentration could be used. It has been also calculated the dissociation constant of 
the dimer Kd.  
Bcl10 CARD has been studied in sodium acetate buffer 5 mM at pH= 4.5 by using a 
set of seven cells for UV experiments with different path lengths (0.01 -5.0 cm) and, 
thus, different volumes of sample solution. For each cuvette, sample concentrations 
were chosen to have a constant number of molecules crossed by the beam and 
circular dichroism experiments were carried out at room temperature starting from a 
stock concentrated solution. CARD concentrations and cell path lengths are reported 
in table 2.I.2. 
 
 
 
Ell.Mol 
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Table 2.I.2: Cell path lengths and relative sample concentrations used for CD experiments 
 
Cell path 
(cm) 
0.01  0.05 0.10  0.20  0.50  1.00  5.00  
[CARD] 
(M) 
2.4•10-4 4.8•10-5 2.4•10-5 1.2•10-5 4.8•10-6 2.4•10-6 4.8•10-7 
 
The spectrum was acquired for each solution and ellipticity was measured after each 
dilution. The results are expressed as mean residue ellipticity, [θ]. 
These experiments show a variation in molar ellipticity dependent from CARD 
concentration and provide the evidences to deduce that a self-association is 
occurring between CARD molecules in solution. 
 
The figure 2.I.8 shows the curve obtained by fitting seven points. Each point is the 
molar ellipticity value observed on CD spectrum for each CARD concentration 
measured in the appropriate path length cell. Molar ellipticity values obtained at 196 
nm are here reported. This wavelength has been chosen because the corresponding 
values obtained give a better evidence of the changes in the spectroscopic 
parameter in dependence of the CARD concentration, but any other wavelength, 
different from isodichroic point, gives a similar value for Kd. Theoretically, the Kd 
values calculated for each wavelength should be approximately the same but 
experimentally, as far from the isodichroic point is the value as higher is the 
confidence. 
 
 
 
 
Figure 2.I.8: Bcl10 CARD. Molar ellipticity measured at 196 nm for different concentrations in different 
path length cells. The increasing concentration corresponds to a decreasing signal. 
 
Starting from literature data [32], reporting CARD-like domains in dimeric form, it has 
been possible to characterize the intrinsic CARD behaviour to dimerize and to 
extrapolate the dissociation constant by using the equation (8). 
By solving such equation, for different values of wavelength from 190 nm to 229 nm, 
it has been possible to obtain the fitting for a dimeric model.  The calculated average 
value for dimerization constant Kd is 18.6 µM. 
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The parametric values a and b were considered for each wavelength to extrapolate 
the dichroic signal, respectively to 0 and to ∞ concentration. In this way it has been 
possible to obtain the theoretical CD spectra for the CARD domain in the theoretical 
monomeric and dimeric form. 
The curve built at 0 concentration shows a typical α-helical behaviour while, for 
infinite concentration a typical random spectrum is observed (figure 2.I.9). 
 
 
 
 
 
 
Figure 2.I.9: Bcl10 CARD theoretical dichroic behaviour. The curve here reported in blue represents 
the theoretical curve obtained by extrapolating the dichroic values at 0 concentration of CARD. In such 
hypothetical condition CARD could be considered as in monomeric form. The curve in magenta 
represents the extrapolation at infinite CARD concentration and is corresponding to a theoretical 
dimeric form. 
 
The data extrapolated from these calculations show that, in response to an 
increasing concentration, a loss of folding is observed and, consequently, a dimeric 
CARD/CARD association should cause unfolding of the domain. This unusual 
behaviour has been also described for other homo-dimerizing proteins in literature. 
 
 
Dimer formation quantification 
 
In order to calculate the percentage of monomeric and dimeric form, the difference 
between the theoretical value corresponding to the 100% momomeric form and the 
theoretical value, corresponding to the 100 % dimeric form was considered. 
Each point of the theoretical α-helical curve reported in figure 2.I.13, represents the a 
value considered for a specific wavelength and the corresponding points of the 
theoretical random curve represents the value b for the same wavelength considered. 
It is possible to calculate the percentage of monomeric form for a given wavelength 
and for each concentration considered for the experiments so far described.  
The equation for 196 nm wavelength is: 
 
([θ]196nm - b) • 100 / (a-b)          (9) 
 
The calculated percentages are reported in table 2.I.3. 
Wavelenght (nm) 
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Table 2.I.3: Calculated values of monomeric form percentage for each CARD concentration. Low 
concentrations correspond to a higher monomeric content and higher concentrations to a lower 
monomeric and, consequently, higher dimeric form. 
 
 
Cell path 
(cm) 
0.01 0.05 0.10 0.20 0.50 1.00 5.00 
[CARD] (M) 2.4•10
-4 4.8•10-5 2.4•10-5 1.2•10-5 4.8•10-6 2.4•10-6 4.8•10-7 
%Monomer 43% 48% 58% 69% 81% 87% 95% 
 
 
From these calculations, it is possible to deduce that CARD domain is present in 
solution in a monomer-dimer equilibrium which is strongly dependent from the 
concentration. For higher concentrations the dimer population increases with a 
concomitant increase in unfolded conformer state. These results are supported by 
the evidence that CARD domain increasing concentrations also changes the 
chromatographic behaviour, during CARD purification. Four different gel filtration 
profiles are reported for CARD applied on the G150 chromatographic column at 
different concentrations. Each point of the curve is obtained by reporting the 
absorbance at 280 nm against the elution volume. 
 
      a) 
0
50
100
150
200
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 b)
0
50
100
150
200
250
300
350
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36  
 
 
                
0
200
400
600
800
1000
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34   
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 
 c) d) 
 
                      
Figure 2.I.10: a) Bcl10 CARD 0.20 mg/mL. b) Bcl10 CARD 0.66 mg/mL. c) Bcl10 CARD 1.78 mg/mL. 
d) Bcl10 CARD 3.50 mg/mL.  
 
As shown in figure 2.I.10, the CARD domain comes out from the gel filtration column 
as a single species, with an elution approximately corresponding to the molecular 
weight of the domain in monomeric form. By increasing the concentration from 0.2 
mg/mL (1.2•10-5 M) to 3.50 mg/mL (2.1•10-4 M), the increasing of a second peak, at 
higher molecular weight, is observed. The second peak is approximately 
corresponding to the dimer. According to the dimerization study previously reported, 
about 70% monomeric form is expected for a concentration corresponding to the first 
chromatogram (a) and a percentage of monomer of 40% in the last chromatogram 
Elution volume (mL) 
mA280 
Elution volume (mL) 
mA280 
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considerated (d), which means to have about 60% dimeric form. The integration of 
the areas of the peaks obtained from CARD gel filtration, at different concentration, 
gives approximately the same percentages of monomeric and dimeric species 
calculated with the equation (9). 
 
 
2.I.3.2    Characterization of protein binding sites 
 
In order to produce more evidences of the self-association occurring between CARD 
molecules, preliminary ELISA assay experiments were performed by immobilizing the 
CARD domain on the ELISA plate and verifying its binding to the biotin-labelled 
CARD, using the biotin-streptavidine system to detect the association. Increasing 
concentrations biotinilated CARD (up to 50.0 µg/mL, in buffer sodium acetate 50 mM 
pH=4.0), were applied to the unlabelled CARD in concentration 1.0 µg/mL, 0.5 µg/mL 
and 0.1 µg/mL, respectively and the absorbance at 490 nm was measured at the UV 
spectrophotometer. The values obtained are reported in figure 2.I.11. 
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Figure 2.I.11. ELISA preliminary assay for CARD/CARD binding. The absorbance intensity measured 
at 490 nm increases for increasing labelled CARD concentrations. The saturation occurs over a 0.5 
µg/mL CARD and 12.5 µg/mL biotinilated CARD (0.63 Abs490). 
 
The absorbance, measured at 490 nm, increases by adding increasing 
concentrations of labelled CARD to the unlabelled domain. This preliminary 
experiment was due to test the better experimental conditions in which CARD is able 
to self-associate. Over 12.5 µg/mL labelled CARD added, the curve represents the 
saturation condition. The condition 0.5 µg/mL CARD has been chosen from the later 
experiments. 
 
Furthermore, in order to identify the specific regions involved in CARD self-
association, a proteolytic digestion with trypsin was carried out for the CARD domain 
to obtain fragments to conveniently employ in a competition assay against the whole 
CARD. The tryptic digestion mix was applied on a RP-HPLC column (data reported in 
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section 2.I.2). The fractions, collected from the tryptic digestion and named from 1F 
to 11F, were tested by competitive ELISA assay to investigate which one contains 
fragments binding to the CARD domain. Unlabelled CARD was immobilized on the 
ELISA plate and the competition mix was applied to the CARD.  
The competition mix is composed of each one of the tryptic fragments and biotinilated 
CARD in two different ratio: 1:1 (w/w) and 10:1 (w/w) in sodium acetate 50 mM 
pH=4.0. The labelled CARD concentration used in this assay, was chosen, before the 
saturation point value (the pre-saturation conditions, determined in the preliminary 
ELISA test, are corresponding to biotinilated CARD concentration of 0.5 µg/mL). In 
figure 2.I.12 the absorbance at 490 nm is reported for each one of the 11 tryptic 
fractions assayed.  
 
 
-0,05
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
0,45
0,5
A
bs
 4
90
 n
m
control 3F 4F 5F 6F 7F 8F 9F 11F
digested fractions
CARD1:1
CARD10:1
 
 
Figure 2.I.12. Competitive ELISA assay. The histogram shows the competition assay of eleven CARD 
fractions obtained from tryptic digestion with CARD domain. For the fractions showing lower 
absorbance the strongest competition is observed. Peaks in light violet correspond to 1:1 (w/w) 
CARD/fragment ratio and in blue is shown to 10:1 (w/w) CARD/fragment ratio. 
 
The first peak of the histogram is corresponding to the only labelled CARD applied to 
the immobilized CARD. It represents the positive “control” for the CARD/CARD 
binding. The assayed competition mix showing a higher absorbance at 490 nm are 
corresponding to a positive binding between CARD and its biotin-labelled 
homologous, detected through the system biotin-streptavidin. The fractions 
competing in this binding show the lowest absorbance at 490 nm because the biotin-
label is not detected. It means that biotinilated CARD, in these competition mix, has 
been brought away from the washing buffer because it is not bound to the CARD-
containing well surface. From this assay the fractions 1F, 3F, 8F, 9F and 11F were 
selected. The fraction shows lower binding properties. In summary, this competition 
assay shows the attitude of the CARD fractions, obtained from CARD tryptic 
digestion, to bind the whole CARD domain. Where a fragment binds the unlabelled 
CARD, immobilized on the ELISA well surface, the biotinilated CARD cannot bind. 
This results in a decreasing signal of absorbance measured at 490 nm.  
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Furthermore, all the digested fractions were characterized by LC-MS to identify the 
CARD region sequences responsible for this competitive binding. The LC-MS profile 
and the corresponding peaks identified by using the program MS-Digest for trypsin 
digestion cleavage (section 2.I.2 table 2.I.1), are reported in the following figure. 
 
 
 
 
 
 
Figure 2.I.13: LC-MS chromatogram of digested CARD domain with the identified sequences. 
 
For the samples collected as fractions 1F, 2F and 10F it was not possible to assign 
any sequence within the “full length” sequence considered. They are most likely 
impurities. The most interesting samples in this study are the fractions 3F, 8F, 9F and 
11F collected from the digestion mix, because they show a competitive binding in 
competitive ELISA assay. With the aim to identify the sequences of the tryptic 
fragments contained in these fractions, and to further investigate their binding 
attitudes, they were characterized by LC-MS. 
As reported in the chromatograms in figure 2.I.13, the digestion fractions named as 
3F contains three identified sequence fragments: CARD [26-49], CARD [32-36] and 
CARD [50-62]. The fraction, named as 8F shows two main peaks, identified as CARD 
[89-98] and CARD [91-98]. For the fraction named as 9F, one sequence was 
identified: CARD [68-77] and for the fraction 11F the sequence CARD [46-58] was 
identified. 
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Figure 2.I.14: LC-MS chromatograms belonging to the fractions 8F(a), 9F(b), 3F(c) and 11F(d). The 
fragments contained in these fractions were identified as CARD [89-98], CARD [91-98], CARD [68-77], 
CARD [26-49], CARD [32-36], CARD [50-62] and CARD [46-58]. 
 
 
        
a) b) 
 
 
Figure 2.I.15: MS spectra of the fraction 8F. a) Fragment E89-K98. [M+2H]2+ = 625.2 m/z, [MH]+ = 
1248 m/z . b) Fragment T91-K98. [M+2H]2+ = 496.7 m/z, [MH]+ = 991.6 m/z   
 37
        
     a) b) 
           
     c) d) 
 
 
Figure 2.I.16: MS spectra of the fractions 3F, 9Fand 11F. a) Fraction 3F, fragment I32-R36, [MH]+ = 
601.6 m/z and b) fragment E50-R62, [M+2H]2+ = 533.6 m/z, [MH]+ =  1065.7 m/z. c) Fraction 9F, 
fragment L68-K77, [M+2H]2+ = 617.4 m/z, [MH]+ = 1232.7 m/z. d) Fraction 11F, fragment I46-R58. 
[M+2H]2+ = 413.2 m/z, [MH]+ = 824.6 m/z. 
 
 
Once the “CARD binding fragments” were identified, their sequences were obtained 
as synthetic peptides in order to test the identified regions against the whole CARD, 
to verify their binding properties. For the first fragment, belonging to the fraction 8F, 
its related longer sequence peptides, CARD [78-98] and CARD [68-98] were also 
synthetized. The fragment CARD [68-77] is belonging to the collected fraction 9F and 
the fragment CARD [26-49] is belonging to the fraction 3F. 
Synthetized sequences: 
CARD [91-98]: TQNFLIQK                    
CARD [78-98]: GLDTLVESIRREKTQNFLIQK 
CARD [68-98]: LLDYLQENPKGLDTLVESIRREKTQNFLIQK 
CARD [68-77]: LLDYLQENPK               
CARD [26-49]: VYLSEKIIAERHFDHLRAKKILSR    
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Competitive ELISA assay with CARD synthetic fragments 
 
Synthetic fragments CARD [91-98], CARD [78-98], and CARD [68-98], were assayed 
in a competitive ELISA to test their competing properties in CARD/CARD association. 
The assay was carried out by following the same procedures reported for the 
competitive assay of CARD tryptic fractions. The results are shown in figure 2.I.17. 
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Figure 2.I.17: Competitive ELISA assay with synthetic fragments. The fragments CARD[78-98], and 
CARD[91-98], show stronger competition properties in the whole CARD domain binding. 
 
 
For this assay, four different concentrations of synthetic fragments were used in the 
competition mix: 1:1, 1:5, 1:10 and 1:20 ratio CARD-peptide. The results shown in 
figure 2.I.17 evidenced that the peptide competition is relatively dependent to the 
concentration used. Higher concentrations peptide in the competition mix result in a 
higher competitive effect in CARD/CARD association. The longer sequence region is 
less competitive in the assayed binding, while, the two shorter peptides have stronger 
competition properties. In order to relate the peptides binding properties to their 
structural behaviour, a circular dichroism characterization was performed. 
 
 
CD characterization of CARD fragments 
 
Once the sequences involved in CARD domain self-association were identified, 
synthetically produced, and tested again to provide the evidence of their attitude to 
compete in CARD-CARD interactions, circular dichroism experiments were carried 
out to investigate the structural behaviour of these fragments. CD experiments were 
performed in buffer solution at pH=4.5, which is the pH value used for all the 
experiments with CARD domain, and pH=7.5, the physiological condition. For both 
the peptides CARD[78-98] and CARD[68-98], the structural behaviour does not 
CARD[68-98] CARD[78-98] CARD[91-98] Control 
A490nm 
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change in dependence of pH. For the peptide CARD [78-98] a typical α-helical 
folding, with two negative bands centered at 208 nm and 222 nm is observed.  
 
 
 
 
 
Figure 2.I.18: Far-UV CD spectrum of the synthetic fragment CARD [78-98] acquired at room 
temperature and pH=4.5. 
 
 
This folding is quite stable. An increase of the temperature up to 40°C does not 
significantly modify the peptide structural behaviour. 
The synthetic fragment CARD [68-98], in the same CD conditions tested for its longer 
analogue, shows a “random” behaviour, with negative band at 200 nm and no 
positive bands in the wavelength region between 190 nm and 200 nm. 
 
 
 
 
 
Figure 2.I.19: Far-UV CD spectrum of the synthetic fragment CARD [68-98] acquired at room 
temperature and pH=4.5. 
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These CD experiments suggest that the longer synthetic CARD fragment, is rather 
unfolded in solution. It is also the weakest competing in ELISA competition assay of 
CARD-CARD association. The shorter sequence, CARD [78-98], shows a prevalently 
α-helical folding and also shows strong competition properties in CARD-CARD self-
association assay. CD experiments on the stronger binding peptide in ELISA 
competition assay, the CARD[91-98] are still in progress. 
 
In order to verify the reliability of the CD experimental results, a sequence aligment 
was performed between Bcl10 CARD sequence and two similar CARDs (from Apaf1 
[25] and RAIDD [33]), whose NMR structure are availeble in Protein Data Bank.  
RAIDD CARD domain, shows a higher omology (~26%) with the CARD studied  in 
this thesis work. From this model structure, it was possible to predict the synthetic 
peptide structural behaviour in the whole CARD sequence and, thus, compare it to 
the structural preferences evidenced in the CD experiments here reported. 
 
 
Figure 2.I.20: The CARD[78-98] peptide (in blue) location in the CARD domain. The image is obtained 
by using weblab wiewer Lite program, considering one of the 15 RAIDD CARD domain NMR 
structures (PDB entry: 3CRD ) as model.  
 
 
The synthetic peptide CARD [78-98] is predicted to have a prevalently α-helical 
folding, and should form an helix-loop-helix within the CARD sequence as shown in 
figure 2.I.20. The results obtained from the circular dichroism characterization of this 
peptide are in agreement with the expected structural behaviour reported in the 
model.  
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Preliminary NMR studies 
 
 
Small peptide systems provide useful models for the elucidation of fundamental 
principles of protein folding and stability, and the conformational analysis of a peptide 
can provide insight into relationship between the three dimensional structure of a 
specific region in solution and its biological activity.  
Preliminary experiments were carried out to look for the best conditions for the NMR 
conformational characterization of CARD[78-98].  
Different concentrations of the peptide (1.0 mM, 0.3 mM, 0.1 mM) were previously 
assayed in neat H2O (10 % D2O), at pH=3.5 and 25°C. In these experimental 
conditions, 1D 1H spectra showed changing of intensity and multiplicity of signals in 
dependance of time. Indeed, spectra acquired for these preparations of the peptide 
after one, two and three days, showed different signals. This behaviour evidenced 
that the peptide CARD[78-98], may exist as a complex mixture of different oligomeric 
states. 
In the second set of experiments, the peptide was studied in the lowest concentration 
possible for NMR experiments at 25°C, in order to avoid any aggregatation. Hence, 
the synthetic fragment was dissolved in buffer sodium acetate 5.0 mM pH=5.5 to 
obtain a concentration of 0.1 mM. In this condition 1D spectrum showed well resolved 
resonances and no aggregation behavior (figure 2.I.21). 
 
 
 ppm 
 
 
Figure 2.I.21: 1D 1H NMR spectrum of CARD[78-98] peptide 0.1 mM in buffer 5.0 mM Na acetate 
pH=5.5, 10% D2O. 
 
 
Furthermore, the same preparation was used to acquire spectra after one, two and 
three days storage at 4°C and no changes were observed in the signals. These 
conditions were chosen to set up further two dimensional NMR experiments in order 
to determine peptide structure. 
 
 42
2.II.     Protein-cell wall interactions: dormancy in Mycobacterium            
tuberculosis 
 
 
2.II.1  Introduction 
 
An interesting challenge is the study of the cellular mechanisms mediated by 
proteinaceous factors and their interactions with the cell wall. Recent studies, 
devoted to the pursuit of chemicals that might give rise to the development of new 
drugs, are focused on these interactions. Many pathologies, such as those caused by 
Streptococcus pneumoniae [34] and Mycobacterium tuberculosis are related to 
interactions between proteins and bacterial cell wall because of their involvement in 
antibiotical resistance. Because of drug resistance, these pathologies are now more 
difficult to treat than they were just a few decades ago. The antibiotics may work by 
interfering in many metabolic activities of the bacterial cell such as cell wall synthesis, 
protein or nucleic acid synthesis, or alter cell wall permeability. Since bacteria have a 
cell wall made up of repeating units of peptidoglycan and human cells lack this 
feature, it would seem that the bacterial cell wall presents an ideal target for 
chemotherapy.  
Among infectious bacterial pathogens, Mycobacterium tuberculosis (MTB), is one of 
the biggest killers, with 2-3 millions deaths per year. One third of the world's 
population is infected with tuberculosis. This is the leading infectious disease cause 
of death and represents more than a quarter of the world's preventable deaths. In the 
lung, the organism is taken up by alveolar macrophages and carried to lymph nodes, 
from where it may spread to multiple organs. Two to eight weeks after infection, cell 
mediated immunity (CMI) and hypersensitivity develop leading to the characteristic 
reaction to the tuberculin test and, in immunocompetent individuals, containment of 
infection. Uncontrolled M. tuberculosis growth in human host is associated with 
extensive lung damage that ultimately causes death by suffocation due to insufficient 
oxygen [35].  
Mycobacteria are usually classified as Gram-positive (no outer cell membrane), non-
motile, pleomorphic rods, related to the Actinomyces. Most Mycobacteria are found in 
habitats such as water or soil. However, a few are intracellular pathogens of animals 
and humans. Mycobacterium tuberculosis, along with M. bovis, M. africanum, and M. 
microti all cause the disease known as tuberculosis (TB) and are members of the 
tuberculosis species complex. Each member of the TB complex is pathogenic, but M. 
tuberculosis is pathogenic for humans while M. bovis is usually pathogenic for 
animals.  
Tuberculosis is currently treated by combining 3-4 drugs with different properties: 
isoniazid, rifampin, streptomycin, as antibacterial activity and a combination of 
isoniazid, rifampin, ethambutol to inhibit the development of resistance. 
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Figure 2.II.1: Electron micrograph of M. tuberculosis 
 
To rationally develop new antitubercular agents, it is important to understand the 
MTB-host interaction to learn how these bacteria circumvent host defences and 
cause disease.  
One of the key events of MTB’s pathogenity is its ability to persist in its host organism 
in a latent state for years after the first phase of infection [35]. 
Actively dividing MTB infection can be cleared by patient’s immune response, but 
once the dormant state has been entered the bacteria are no longer cleared. What 
are the bacterial determinants necessary for persistent infection and what is the 
physiological state of tubercle bacilli during latent infection remain unclear. This 
clinical latent state of infection is usually called “dormancy”. Understanding and 
controlling the entry and exit from dormancy is important in the development of new 
anti-tubercular therapies. Dormancy has been described as a state of low metabolic 
activity in which cells are alive but fail to grow under standard culture conditions. 
There is ample circumstantial evidence from observation of tuberculosis in humans 
and animals that it is capable of adapting to prolonged periods of dormancy in 
tissues, becoming responsible for latency of the disease itself. Furthermore, the 
dormant bacilli are resistant to antimycobacterial agents. Although tuberculosis 
persistence and reactivation play significant roles in the pathogenesis of the disease, 
relatively little is known regarding the molecular mechanism which regulate 
mycobacterial physiology in these disease states of persistence [36-38].  
It has been suggested that the ability of MTB to shift down into nonreplicating stages 
is responsible for the ability of tubercle bacilli to lie dormant in the host for long 
periods of time, with the capacity to revive and activate disease at a later time, when 
conditions are more favourable [39]. The latency of the bacterium has been 
extensively studied but reactivation from this state of dormancy is still an important 
field of investigation. A probable mechanism of exit from the latent state involves, for 
MTB, an attack of the bacterial cell wall by a protein component, denoted as 
Resuscitation Promoting Factor (Rpf). Indeed, it has been demonstrated, both for 
MTB and for the bacterium Micrococcus luteus that these Rpfs are responsible of 
increasing the number of colony-forming units when added to dormant cultures and is 
active at picomolar concentrations [40-43].  MTB encodes a family of five proteins 
(Rpf A-E) which share homology with the Rpf found in M. luteus. In vitro studies of M. 
luteus reactivation show that MTB’s Rpfs are potential regulators of persistence and 
reactivation [40, 44]. All the Rpfs share a common core domain located in the C-
terminal region of the proteins.  
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Figure 2.II.2. Multiple sequence alignment of Rpf domain region and c-type lysozymes. Structure 
codes are from the Protein Data Bank (http://www.rcsb.org/pdb/) and sequence codes are from the 
Mycobacterum tuberculosis genome for Rv2389c, Rv2450c, Rv1884c, Rv1009 and Rv0867c. 
 
 
The solution NMR structure for the 108-residues domain of RpfB from M. tuberculosis 
has been solved by heteronuclear multidimensional NMR. Such a structure has been 
compared to that of the c-type lysozyme. 
 
 
 
 
Figure 2.II.3 . Comparison of RpfB catalytic C-terminal domain and lysozyme catalytic site .(a) 
Structure superimposition in the cleft area of the RpfBc (red) and a c-type lysozyme (PDB entry 1LMQ; 
blue). The catalytic glutamate at the C-terminal end of the first helix is at the same position in RpfBc 
and lysozyme (Glu292 and Glu35, respectively).  
 
 
The similarity of this region domain to lysozyme suggests that RpfB has a catalytic 
mechanism common to lysozyme and, thus, a muralytic activity. 
Biochemical studies indicate that the conserved active site glutamate is important for 
the resuscitation of dormant cultures of M. luteus. 
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Figure 2.II.4: Catalytic mechanism of lysozyme. 
 
 
It has been also reported that the catalytic site of Rpf B can bind the oligosaccharide  
N, N’, N”-triacetylchitotriose (tri-NAG), the trimer of N-acethylglucosamine (NAG), one 
of the two sugars that make up the polysaccaride portion of peptidoglycan [43]. 
 
This evidence suggests that the oligosaccharide cleavage is probably the signal for 
revival from dormancy and the glutamate is essential for in vivo activity. 
One hypothesis about the correlation between muralytic activity and resuscitation, is 
that the products of such hydrolysis incite cells to divide but what is the nature of the 
signal that those proteins generates and how is the signal relayed to or detected from 
the cells is still to be clarified. It has been also proposed that the substrate of Rpfs 
catalytic domain may be a modified form of peptidoglycan found only in dormant 
bacteria. Any modification of the peptidoglycan that confers resistance to antibacterial 
enzymes as lysozymes and amidases could have a role in pathogenesis and such a 
modification could play a similar role in MTB virulence. So far no crystal structures 
have been reported in literature for any of the Rpfs. In addition, none of the Rpf forms 
from M. tuberculosis have shown to display muralytic activity.  
 
Several Rpf forms from M. tuberculosis have been studied in this thesis work. These 
studies are aimed at a deeper characterization of both structural and functional 
properties of these proteins. Understanding the properties of these proteins in 
relation to their interactions with M. tuberculosis cell wall is of fundamental 
importance for the study of reactivation of the bacterium itself. In turn, this step 
provides the bases for the identification of molecules which are able to inactivate Rpf 
and, therefore, to keep the disease in a dormant state.  
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2.II.2 Methods 
 
 
Choice of host for protein amplification 
 
The use of recombinant proteins is generally preferred to facilitate purification and 
detection of the recombinant proteins. The more that is known about the 
characteristics of a protein, the more easily it can be isolated and purified. 
Consequently, fusion proteins are simple and convenient to work with and, for many 
applications, a single purification step, using a commercially available affinity 
chromatography column, is sufficient. The choice of host depends upon the specific 
requirements and applications for the recombinant protein. Bacteria like Escherichia 
coli are commonly employed because many references and much experience is 
available on them, a wide choice of cloning vectors is possible and they are 
organisms easy to grow with high yields. Therefore, all studies here reported on Rpf 
proteins have been carried out using Escherichia coli as a host. 
 
 
PCR protocol used for Rpfs cloning 
 
Choice of the primers: PCR primers are usually 15-30 nucleotides in length. Longer 
primers provide higher specificity. The GC content should be 40-60%. More than 
three G or C nucleotides at the 3'-end of the primer should be avoided, as 
nonspecific priming may occur. The primer should not be self-complementary or 
complementary to any other primer in the reaction mixture, in order to avoid primer-
dimer and hairpin formation. The melting temperature of flanking primers should not 
differ by more than 5°C, so the GC content and length must be chosen accordingly.  
The rpf B gene was amplified from MTB genomic DNA using 5 pmol of each primer 
described in table 2.II.1. 
Estimation of the melting and annealing temperatures of primer: if the primer is 
shorter than 30 nucleotides, the approx. melting temperature (Tm) is calculated using 
the following formula: Tm= 4 (G + C) + 2 (A + T). Annealing temperature should be 
approx. 5°C lower than the melting temperature. 
MgCl2 concentration: since Mg2+ ions form complexes with dNTPs, primers and 
DNA templates, the optimal concentration of MgCl2 has to be selected for each 
experiment. Too few Mg2+ ions result in a low yield of PCR product, and too many 
increase the yield of non-specific products The recommended range of MgCl2 
concentration is 1-4mM, under the standard reaction conditions specified.  
dNTPs: the concentration of each dNTP in the reaction mixture is usually 200 µM. It 
is very important to have equal concentrations of each dNTP (dATP, dCTP, dGTP, 
dTTP), as inaccuracy in the concentration of even a single dNTP dramatically 
increases the misincorporation level.  
Taq DNA Polymerase: usually 1-1.5u of Taq DNA Polymerase are used in 50µl of 
reaction mix. Higher Taq DNA Polymerase concentrations may cause synthesis of 
nonspecific products.  
Cycling Conditions: the complete denaturation of the DNA template at the start of 
the PCR reaction is of key importance. The initial denaturation should be performed 
over an interval of 1-3min at 95°C if the GC content is 50% or less. This interval 
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should be extended up to 10 min for GC-rich templates. Usually denaturation for 0.5-
2min at 94-95°C is sufficient. If the amplified DNA has a very high GC content, 
denaturation time may be increased up to 3-4min. The primer annealing step is 
carried out at temperatures 5°C lower than the melting temperature of primer-
template DNA duplex. Incubation for 0.5-2min is usually sufficient. The extending 
step is performed at 70-75°C. The rate of DNA synthesis by Taq DNA Polymerase is 
highest at this temperature. Recommended extending time is 1min for the synthesis 
of PCR fragments up to 2 kb. When larger DNA fragments are amplified, the 
extending time is usually increased by 1min for each 1000 bp. The number of PCR 
cycles depends on the amount of template DNA in the reaction mix. For less than 10 
copies of template DNA, 40 cycles should be performed. If the initial quantity of 
template DNA is higher, 25-35 cycles are usually sufficient. After the last cycle, the 
samples are usually incubated at 72°C for 5-15min to fill-in the protruding ends of 
newly synthesized PCR products. For Rpfs cloning, the following PCR cycle program 
was used: 95°C for 2 min, then 30 cycles of 95°C for 30 s, 56°C for 30 s and 72°C for 
1 min and then 72°C for 10 min. using 200 µM dNTPs mix, 2.5 U standard Taq 
polymerase,  200 ng of template, 4 µM MgCl2 for a total reaction mixture of 50 µL. 
The amplified PCR samples were purified using preparative agarose electrophoresis 
(1% agarose gel).  
  
 
Table 2.II.1:Rpfs used primers and protein information. *Rpf Bcd refers to the catalytic domain of RpfB. 
 
 
Protein Gene name 
and length  
Protein length 
(MW) 
P.I. Primers  
Rpf B Rv1009 
(999bp) 
333 a.a.(35162 Da) 5.14 5’-CAT GCC ATG GGA GTC GAC GGA 
ACC GCG ATG-3’  
5’-CCC AAG CTT ATC AGC GCG CAC 
CCG CTC-3’ 
*Rpf Bcd Rv 1009 
(255 bp) 
85 a.a. (9001 Da) 4.85 5’-CAT GCC ATG GGA ATC GAC GGA 
AGC ATC TGG GA-3’ 
Rpf C Rv 1884c 
(441bp) 
146 a.a.(14989 Da) 
 
9.14 
 
5’-GAT GGG TCT CAC ATG ACT TCC 
GGC GAT ATG TCG AG-3’ 
5’-CCC AAG CTT ATC AGC GCG GAA 
TAC TTG CC-3’ 
 
 
Choice of vectors 
 
In order to clone the gene of interest all engineered vectors have a selection of 
unique restriction sites downstream of a transcription promoter sequence. The choice 
of vector family is governed by the host. Once the host has been selected, many 
different vectors are available for consideration, from simple expression vectors to 
those that secrete fusion proteins. Fusion His-tag protein production method is the 
most employed because targeting information can be incorporated into a tag which 
provide a marker for expression and purification. Purification can be easily obtained 
by using affinity chromatography under denaturing or non-denaturing conditions. 
Commonly used vectors for His-tagged fusion proteins are pET vectors containing 6 
histidine. In pET vectors, target genes are cloned under control of strong 
bacteriophage T7 transcription and translation signals, and expression is induced by 
providing a source of T7 RNA polymerase in the host cell. 
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Figure 2.II.5. The basic architecture of an E. coli expression vector 
 
 
The plasmid should have an antibiotic-resistance marker and, by supplementing the 
medium with the appropriate antibiotic, it is possible to kill plasmid-free cells. 
The vector should contain a regulatory gene (repressor). The lac-derived promoters 
are frequently used because they can be controlled by the insertion of a lac-operator 
sequence downstream the promoter. The origin of replication controls the plasmid 
copy number. The promotor initiates transcription and is positioned 10-100 
nucleotides upstream of the ribosome binding site. The ideal promoter is strong 
enough to allow product accumulation up to 50% of the total cellular protein, it has a 
low basal expression level, it is easy to induce. Then the vector contains a 
transcriptional terminator (that reduces unwanted transcription) and a Shine-Dalgarno 
sequence which is required for translation initiation and is complementary to the 3'-
end of the 16S ribosomal RNA. The consensus sequence is: 5'-TAAGGAGG-3'. It is 
positioned 4-14 nucleotides upstream the start codon with the optimal spacing being 
8 nucleotides. Initiation point of translation is allowed by a start codon (usually ATG 
or GTG). For the termination of translation there are 3 possible stop codons but TAA 
is preferred because it is less prone to read-through than TAG and TGA. His-tag 
fusion proteins vectors have a specific site of seven residues sequence (Glu-X-X-Tyr-
X-Gln/Ser) recognised by TEV protease. This cleavage allows tag removal after 
purification. The cleavage site should be surface exposed. The vector should also 
contain the restriction enzymes cleavage sites to allow insertion of the gene, which 
must be cleaved with the same enzymes. Restriction sites are specific target 
sequences which are palindromic (both strands have the same nucleotide sequence 
but in antiparallel directions) and this is one of many features that makes them 
suitable for DNA manipulation. Any DNA molecule will contain the restriction enzyme 
target just by chance and therefore may be cut into defined fragments of size suitable 
for cloning. 
 
PCR Rpf B and Rpf Bcd products were digested with 1 U Nco I and 1 U Hind III with 
the appropriate buffer (according to the manufacturer protocols). 
Nco I cleaves into the sequence C^CATGG and Hind III cleaves into the sequence 
A^HGCTT. The digestion mix was incubated for 1 hour at 37°C and purified 
(Qiagen's QiaQuick purification kit). The gene was cloned into the corresponding 
sites of pETM-11 vector (previously digested with the same enzymes in order to 
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obtain the complementary restriction sites) to produce N-terminally His-tagged Rpf 
protein. Similar conditions were used for Rpf C cloning. However additional cloning 
using the pET-20 vector was also performed for Rpf C. 
pETM-11 is used to obtain (His)6-tag fusion proteins while pETM-20 produces (His)6-
tag and thioredoxin fusion proteins. Expressing a protein with a fused thioredoxin is 
preferable to increase protein solubility. As the yield of protein Rpf C obtained by 
cloning rpf C gene in pETM-11 was not high because of solubility problems, the same 
gene was also cloned in pETM-20. The complete map of both the vectors is reported 
in figure 2.II.6. 
 
 
 
 
Figure 2.II.6: pETM-11 and pETM-20 vectors maps available from the website (http://www.embl 
hamburg.de/~geerlof/webPP/vectordb/bact_vectors/maps_seqs_mcs/pETM.pdf). 
 
 
Expression  
 
A complete expression screening was carried out by transforming rpf B and rpf Bcd in 
pETM-11 in different E. coli strains: BL21 (DE3), BL21 RP, BL21 RIL, BL21 pLysS, 
BL21 pRARE2, Rosetta (DE3) pLysS, BL21 cc1, cc2, cc3, cc4, cc5. 
From this screening was selected BL21 (DE3) strain as the best strain to obtain a 
good expression and higher solubility of the protein. Cultures of Rpf B in BL21 (DE3) 
were grown in Luria Bertani (LB) medium containing kanamycin. The expression was 
induced by adding 1 mM isopropyl thio-β-D-galactoside, IPTG (Sigma) after 3 hours 
incubation at 37°C and at 0.8-1.0 OD600. The cultures were grown in a shaking 
incubator overnight at 25°C up to 6.5-7 OD600. Cell suspensions were centrifuged (in 
a Beckman centrifuge) at 4°C and at 6000 Rpms for 60 min. 
The same expression screening was carried out for rpf C cloned in both the plasmids 
pETM-11 and pETM-20. From this screening was selected BL21 (DE3) strain as the 
best strain to obtain a good expression and higher solubility of the protein Rpf C in 
both vectors. Cultures of Rpf C in BL21 (DE3) were grown in LB medium and induced 
with IPTG after 3-4 hours incubation at 37°C. After induction, the cultures were grown 
overnight at 25°C up to 5.5-6.0 OD600. 
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Purification strategy 
 
Protein purification is carried out to isolate the protein of interest from a complex 
mixture contained in the microbial culture. The protein has to be brought into solution 
by breaking the tissue or cells containing it (cell lisys). After this extraction process 
soluble proteins will be in the solvent, and can be separated from cell membranes, 
DNA etc. by centrifugation. The extraction process also extracts proteases, which will 
start digesting the proteins in the solution. If the protein is sensitive to proteolysis, it is 
usually desirable to keep the extract cooled, to slow down proteolysis and use a 
protease inhibitor. The purification process frees the protein from non-protein parts of 
the mixture, and finally separate the desired protein from all other proteins. 
Separation steps exploit differences in protein size, physico-chemical property and 
binding affinity. Usually a protein purification protocol contains one or more 
chromatographic steps. Different proteins interact differently with the column material, 
and can thus be separated by the time required to pass the column and they are 
detected as they are coming of the column by their absorbance at 280 nm.  
 
Purification protocol for His-tagged proteins 
 
If the protein of interest has been cloned and expressed as His-tag fusion protein it 
can be easily selected among the others by using affinity chromatography purification 
strategy. It consist in chelating the His-tag upon an activated chelating resin by 
incubating the lisate with affinity media such as NTA-agarose. Chelating Sepharose, 
when charged with Ni2+ ions, selectively retains proteins if histidines are exposed on 
the protein surface. The polyhistidine-tag binds with micromolar affinity the activated 
medium. This procedure allows discriminating the selected His-tagged protein while 
the other proteins that do not specifically interact with the nickel resin are easily 
eluted with phosphate or TRIS buffer. The washing efficiency can be improved by the 
addition of 10-20 mM imidazole. His-tag fusion proteins can be desorbed with buffers 
containing 150-300 mM imidazole. Imidazole competes with his-tags in binding Ni2+ 
and allows protein elution. 
 
 
Purification protocol for Rpfs 
 
The pellets were resuspended in buffer 50 mM tris pH= 7.8, 300 mM NaCl, 3 mM 
imidazol, 10 µg/mL DNase and protease inhibitor (1 mM PMSF protease inhibitor mix 
to the lysis solution), and lysed by sonication for 5 min. The lysate was centrifuged at 
18 000 Rpms for 90 min at 4°C (in a Sorvall centrifuge) to separate the insoluble part 
(pellet) from the supernatant containing the soluble protein fraction. The supernatant 
was applied to a Ni2+-chelate affinity chromatography column (Hi-trap 5 mL), 
equilibrated with buffer 50 mM tris pH= 7.8, 300 mM NaCl, 3 mM imidazol, 5% 
glycerol and washed with 20 column volumes of the same buffer. 
To prevent non-specific binding of host cell proteins, 3 mM imidazole was included in 
the extraction buffer. This procedure is useful when working with (His)6 fusion 
proteins. The protein was eluted with buffer 50 mM tris pH=7.8, 300 mM NaCl, 300 
mM imidazol, 5% glycerol. The eluted fraction were dialyzed against 2 L low salt 
dialysis buffer 20 mM tris pH= 7.8, 150 mM NaCl, 5% glycerol and treated with TEV 
protease 1:50 (molar ratio) at 4°C overnight in presence of 1 mM DTT. 
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TEV protease and His-tag was removed by applying again the protein solution to a 
Ni2+ column and the flow through was collected, concentrated to 5 mL and injected in 
FPLC system (ÄKTA Explorer) at 4°C on a gel filtration Superdex 200 column 
(Amersham Pharmacia) equilibrated in buffer 50 mM tris pH= 7.8, 300 mM NaCl, 5% 
glycerol. The pure fraction was collected and concentrated to 3 mg/mL.  
The protein amount was determined spectrophotometrically by measuring the 
absorbance at 280 nm. The yield of Rpf B protein is about 2 mg for each liter culture. 
The purification protocol used for Rpf C is the same used for Rpf B and Rpf Bcd but 
the former was purified on FPLC by using a POROS MC 20µm PEEK 4.6 mm x 100 
mm Ni-chelating column and a Superdex 75 column for gel filtration on ÄKTA purifier 
at 4°C. The yield of Rpf C in pETM-11 is quite poor while cloning the protein in 
pETM-20 makes it much more soluble. The chromatogram and the acrylamide gel 
reported in section 2.II.3.1 are referred to Rpf C in pETM-20.  
 
Circular Dichroism experiments protocols 
 
CD experiments for Rpf B, its catalytic domain Rpf Bcd and Rpf C were carried out in 
buffer phosphate 10 mM pH= 7.5, 150 mM NaCl by using a protein concentration of 
4.0 µM, on a Jasco J-810 spectropolarimeter equipped with Peltier system for 
temperature control. All the buffers and solutions were previously filtered with a 0.45 
µM filter to avoid any dust and placed in 0.1 cm cell.  
 
Parameters: 
 
Wavelength range: 260 nm-195 nm, data pitch: 0.1, acquisition: continuous, scan 
speed: 100 nm/min, response: 4 s, band width: 1 nm, accumulation: 3 
 
 
Activity assay protocols 
 
The lysozyme-kike activity was tested for the truncated Rpf B in buffer 50 mM sodium 
citrate, 5 mM MgSO4 at  pH= 7.8 by incubating the protein at 37 °C with the substrate 
4-methylumbelliferyl-β-D-N, N’, N”-triacetylchitotriose (MUF tri-NAG) for 3 hours. The 
fluorescence emission of the catalytic reaction producing  4-methylumbelliferone, was 
measured at 455 nm. This wavelength is the maximum emission wavelength for the 
fluorescent product of this reaction, according to manufacturer information sheet 
(Sigma-Aldrich, Germany). The experiments were carried out in Labsystems 384 
black cliniplates, in a Tecan (Durhan, NC) ULTRA Evolution Multi-Detection 
Microplate Reader instrument for fluorescence intensity (UV and VIS range) top & 
bottom detection. 
 
Parameters: 
 
Excitation: 360 nm 
Emission: between 400 nm and 500nm 
Temperature control: 37°C 
 
Protein concentration: 10 µM in 50 µL total volume  
Substrate concentration: from 0.5 µM to 10 µM 
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The second set of experiments were performed on a Varian Cary Eclipse 
spectropolarimeter. Spectra were acquired in 10 mm (500 µL) fluorescence cuvettes 
covered with caps. The protein Rpf B (2 µM) in buffer50 mM sodium citrate, 5 mM 
MgSO4 at  pH= 7.8, was incubated overnight at 37° C with 20 µM MUF tri-NAG. 
 
 
Dynamic light scattering experiments  
 
Hydrodynamic radius (RH) measurements were made with a DynaPro99 MSX 
instrument (Wyatt Technology) equipped with a gallium aluminium arsenide laser and 
with Peltier temperature control for accelerated stability studies. Samples (60 µL) 
were filtered with a 0.22 µm filter, because dust particles may result in large 
fluctuations in the instrument readings, and placed directly into a black quartz 
cuvette, waiting for 15 mins for sample stabilization and approximately 30 
measurements were collected at 4°C. Histogram of percentage intensity (% I) versus 
RH were calculated using Dynamics data analysis software (Protein Solutions), and 
intensity-weighted mean RH values were obtained for each subpeak.  
 
Conditions: 
DLS measurements were performed for both Rpf B and Rpf C in buffer 50 mM TRIS 
pH= 7.8, 300 mM NaCl, 5% glycerol. 
 
The histograms obtained from these experiments are reported in section 2.II.3.2. 
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2.II.3 Results and discussion 
 
 
2.II.3.1 Cloning, expression and purification of Resuscitation-
Promoting Factors 
 
Rpf-like proteinaceous factors are presents in several G+C Gram-positive bacteria 
such as the non-sporulating Mycococcus luteus and in Mycobacteria as M. 
Smegmantis, M. tuberculosis and its related M. bovis.  While M. luteus possesses 
one single gene encoding for one Rpf protein, M. tuberculosis contains five rpf-like 
genes, designated as rpfA-E (http://genolist.pasteur .fr/Tuberculist) which are 
expressed by actively growing cells. The predicted rpf-like gene products of M. 
tuberculosis have very close characteristics and properties to those of Rpf from M. 
luteus and they are also able to resuscitate dormant cultures at picomolar 
concentrations. It has been proposed [45] that these five Rpf-like proteins from M. 
tuberculosis may be partially redundant and that, none of the five rpf-like genes is 
essential in MTB, in contrast to the single M. luteus rpf. 
 
A secondary structure prediction investigation of all five Rpf forms has been carried 
out as a preliminary study of feasibility. As a result, we evidenced that both Rpf A  
and RpfE contain series of Ala-Pro-rich sequence repeat, which are likely 
unstructured. For this reason, these two proteins were considered as a difficult 
protein for structural characterization purposes. Similarly, RpfD is predicted to contain 
a large non-structured region. In contrast, Rpf B and Rpf C are predicted to exhibit a 
rather defined fold. Furthermore, all the Rpfs contain an N-terminal signal P 
sequence and/or a membrane anchor. A signal peptide, also called “signal P”, is a 
short (3-60 amino acids long) peptide chain that directs the post-translational 
transport of a protein to other locations in the cell. Protein sequences containing 
signal peptides or membrane anchors are often difficult to express and purify as 
soluble proteins. 
At first, full length forms of Rpf B and Rpf C were cloned and a complete expression 
screening, in all the available E. coli strains, was performed. However, the expression 
of soluble protein has been too poor to scale up. Therefore, truncated constructs 
have been designed for Rpf B and Rpf C, avoiding signal P fragments predicted in 
the N-terminal region between residues 1 and 30.  
Truncated versions of these proteins, lacking their N-terminal 30 residues, were 
cloned.  
In order to clone the genes of interest, the host and the vector were previously 
selected among those available to obtain fusion proteins. E. coli was chosen as host 
because is fast and easy to grow, it is compatible with a wide choice of cloning 
vectors and gives high yields. The use of pET vectors allowed obtaining the proteins 
of interest as fusion proteins, containing a tag of known size and biological function. 
Fusion His-tag protein production method is the most employed because targeting 
information can be incorporated into the tag which provide a marker for expression 
and purification. Purification can be then obtained by using affinity chromatography. 
All rpf genes have been amplified from MTB genomic DNA using the primers and the 
PCR cycle program reported in table 2.II.1 in section 2.II.2. 
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Furthermore, a shorter construct was designed, cloned, expressed and purified for 
the shorter C-terminal domain of Rpf B, the fragment Rpf B [280-362], named as Rpf 
Bcd. This fragment corresponds to the cathalytic domain of the protein. 
The amplified PCR samples were digested with Nco I and Hind III as the primers 
were designed with these specific restriction sites and cloned into the corresponding 
sites of pETM-11 vector to produce N-terminally His-tagged Rpf protein.  Additionally, 
the rpf C gene was cloned in pETM-20, a vector containing thioredoxin as fusion 
protein and a fusion His-tag in order to improve protein solubility. The first  cloning of 
Rpf C in pETM-11 produced low soluble protein yields.  For all proteins, sequences 
were checked using the sequencing facilities available at EMBL Heidelberg and the 
plasmid with the gene has been transformed into E. coli DH5α. 
A complete expression screening was carried out for all the targets in the available E. 
coli strains cited in Methods section. From these screenings the strain BL21 (DE3) 
was selected among the others because it gave the best yield of soluble protein and 
the cultures were grown in Luria Bertani medium and induced with IPTG.  As proteins 
were cloned and expressed as His-tag fusion proteins, they were purified by affinity 
chromatography purification strategy, chelating the His-tag upon an activated 
chelating resin, charged with Ni2+, and desorbing the His-tagged fusion proteins with 
buffers containing 150-300 mM imidazole. After the first step of purification the His-
tag was removed by cleaving it away with TEV protease in a lower salt buffer. 
Furthermore, an additional step of purification, on a gel filtration column was carried 
out to check the aggregation of the proteins. The first purifications performed by gel 
filtration for both Rpf B and Rpf C revealed a significant amount of aggregate in the 
protein preparation. The aggregate part was eluted out  in the void volume of the 
column, at retention times corresponding from the calibration of the column, to high 
molecular weights. The purification condition were optimized by adding 5% glycerol 
to all the buffers used, from the lysis to the final gel filtration and by adding 3% 
imidazol to the lysis buffer to prevent non-specific binding to the Ni activated resin 
during the first step of purification. Furthermore, all the purification steps were 
performed at low temperature (4°C) and in one day to avoid any degradation of the 
protein occurring after a long time storage. The optimisation, to obtain soluble and 
much more stable protein, is confirmed by gel filtration ad DLS measurements here 
reported.  
The pure fractions of Rpf B, Rpf Bcd and Rpf C, were collected and concentrated to 3 
mg/mL. The protein amount was measured spectrophotometrically by measuring the 
absorbance at 280 nm and the proteins were electrophoretically identified on a 
acrylamide gradient gel (8-20% acrylamide) and stained with Coomassie. The yield of 
Rpf B and Rpf Bcd is about 2 mg for each liter culture and for Rpf C, 1.5 mg protein 
was obtained for 1 liter culture. Data here reported for Rpf C are relative to the gene 
cloned and expressed in pETM-20. The thioredoxin fusion protein increased protein 
solubility and was removed by the TEV protease, together with the His-tag, before 
the last step of purification. 
As gel filtration is the preferable technique to separate molecules for their size, it was 
used as the last step of purification to avoid any possible aggregate from the protein 
preparation. 
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Figure 2.II.7: FPLC chromatogram obtained from Rpf B gel filtration after the optimization of the 
purification and relative acrylamide gel. The main peak corresponds to the molecular weight of the 
protein and the lower peak is belonging to a small amount of aggregate or high molecular weight 
impurities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.II.8: FPLC chromatogram obtained from RpfC gel filtration after the optimization of the 
purification and relative acrylamide gel. The main peak corresponds to the molecular weight of the 
protein. 
 
~35 kDa 
~15 kDa
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Figure 2.II.9: FPLC chromatogram of Rpf Bcd gel filtration and its acrylamide gel. 
 
As shown in chromatograms here reported, after the optimization of proteins 
purification conditions, the amount of aggregate, remains quite low. 
The proteins were usually used for further experiments immediately after their 
purification, to avoid any degradation and/or aggregation. When it has been not 
possible to employ fresh preparation, the proteins were frozen in 5-10% glycerol and 
stored at -80°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 9 kDa 
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2.II.3.2. Dynamic light scattering and circular dichroism 
studies 
 
Dynamic Light Scattering (DLS) 
 
In order to determine the aggregation eventually occurring in protein preparation, 
several experiments were performed by dynamic light scattering. This technique is, in 
principle, capable of distinguishing whether a protein is a monomer or dimer. It allows 
calculating the absolute molecular weight for determining the oligomeric state of a 
protein for a particular solution condition or preparation. Usually, for proteins, 
absolute molecular weight is measured by chromatography where the elution time of 
the peak is compared to the elution of a standard in the same column but this 
technique may require significant amount of sample and several hours to make 
measurements. With light scattering there is no reference needed. If the 
concentration and the refractive index increment of the sample are known, then from 
the absolute amount of light scattered (the intensity) is possible to determine the 
absolute molecular weight, or molar mass. It is called absolute, because no further 
assumption has to be made about the sample or its behavior with respect to another 
measurement technique (as would be the case for a native gel or HPLC run). 
Oligomer formation, aggregation or conformation of the protein molecules as well as 
the amount of impurities in the solution are critical parameters in successful 
crystallization. Thus, DLS is widely used prior to protein crystallography [46, 47] to 
assess whether protein samples are able to form crystals. It is also a practical 
method to investigate conformational changes, folding kinetics, [48] oligomerization, 
thermostability, [49, 50] and the liquid-phase complex formation [51] of proteins. 
Together with MS, it can be a useful method to confirm the observed characteristics 
of the protein molecules. DLS is a quick, non-destructive and sensitive method 
requiring relatively small amounts of purified material, typically less than 1mg and it is 
almost all automatized. It also gives the possibility to analyze samples containing 
broad distributions of species of widely differing molecular masses (a native protein 
and various sizes of aggregates), and to detect very small amounts of the higher 
mass species (<0.01% in many cases). However, the analysis might be difficult for 
non-rigid macromolecules. Commercial "particle sizing" systems mostly operate at 
only one angle (90°) and use red light (675 nm). Usually in these systems the 
dependence on concentration is neglected. 
 
The percentage intensity versus RH was calculated using Dynamics data analysis 
software (Protein Solutions), and intensity-weighted mean RH values were obtained 
for each subpeak. These calculations were made by the instrument, which generates 
the corresponding histogram of the percentage intensity versus the hydrodynamic 
radius. The polydispersion index is a strong indicator of monodispersity of a solution. 
It can be calculated as the ratio between the dispersity of the peak and the protein 
hydrodynamic radius. If this index is lower than 0.15, the solution is considered as 
monodisperse. Above 30-35% it is a polydisperse solution. The peak always come to 
a higher MW than the true MW, unless the protein is a perfect sphere, due to 
unaccounted for additional rotation friction. A protein does have higher chances to 
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crystallize if it is monodisperse. It has been reported about crystallized solutions with 
a polydispersion index of 20-25%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.II.10: Histogram obtained for Rpf B measurement. The percentage of intensity is reported as 
a function of the hydrodynamic radius. 
 
 
 
 
 
                          
 
 
 
 
 
 
 
 
 
 
 
Figure 2.II.11: Histogram obtained for Rpf C measurement. The percentage of intensity is reported as 
a function of the hydrodynamic radius. 
 
Polydispersion indexes were calculated both for Rpf B and Rpf C. As shown in figure 
2.II.10, purification of Rpf B resulted in a significantly pure protein preparation, and 
no aggregation is registered, with a polydispersion index of 20.7 %. A slightly higher 
polydispersion, close to 29%, was observed for RpfC (figure 2.II.10).  Furthermore, 
beside the existence of a peak in correspondence to low RH (figure 2.II.11), which is 
commonly observed in protein preparations, it is also evidenced the presence of a 
small amount of impurities at high Rh values (close to 2601 nm), which is likely 
constituted by protein aggregates. These experiments were repeated for each fresh 
preparation of the protein to check if aggregation problems were occurring, before 
using the prep for activity assays. An even small amount of aggregate could affect 
fluorescence activity assays, as reported also in literature, [42] for similar assays. 
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Circular Dichroism (CD) spectroscopy experiments 
 
In order to investigate Rpfs’ structural behaviour in solution, several CD experiments 
were carried out for these proteins in 50 mM pH=7.5 phosphate buffer, 150 mM 
NaCl. Measurements were carried out on a Jasco J-810 spectropolarimeter equipped 
with Peltier system for temperature control. The first set of experiments was due to 
previously verify whether Rpf B and Rpf C are folded in buffer solution and in the 
condition cited. With this aim spectra were acquired for fresh protein preparations at 
room temperature (20°C). 
 
 
          
 
  
Figure 2.II.12: Rpf B 4 µM far UV-CD spectrum at room temperature (20°C) 
 
 
 
  
 
 
 
 
 
 
   
 
 
 
 
 
Figure 2.II.13: Rpf C 4 µM Far UV-CD spectrum at room temperature.  
 
 
As shown in figure 2.II.12 and 2.II.13, both the proteins are folded in solution at pH= 
7.5 and show prevalently α-helical behaviour. Higher α-helical content in the 
condition experimented, is observed for Rpf B. Its spectrum shows a strong negative 
band at 208 nm, a visible shoulder at 222 nm and a positive band at 195 nm. These 
values are typical for α-helical dichroic behaviours. Rpf C seems to have lower α-
helical content (the gap between the minimum at 208 nm and the shoulder at 222 nm 
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is not so evident), even if it is most likely folded in the experiment conditions. After 
this previous characterization, further experiments were performed on the protein Rpf 
B, in order to investigate the stability of this protein. A thermic denaturation of the 
protein was carried out by following the molar ellipticity at 222 nm (the wavelength 
that typically represents an α-helical folding), in a range of temperatures between 4°C 
and 80°C by increasing the temperature of 1°C each minute.  
 
 
 
     
 
 
Figure 2.II.14: Rpf B 4µM temperature scan measurements from 4°C to 80°C at 222nm 
 
 
The temperature scan reveals a loss of folding for the protein Rpf B from 23°C to 
60°C. A new spectrum was acquired for the protein after the scan measurements at 
80°C, where a complete unfolding of the protein was expected. The figure 2.II.14 
shows the overlay of the spectra acquired before and after temperature unfolding. 
The loss of folding is evidenced from the main negative band shift from 208 nm to 
202 nm and the gap between the negative bands becomes less relevant. 
Furthermore, the positive band around 195 nm became negative. 
 
           
    
 
Figure 2.II.15: Overlay of Rpf B spectra at 4°C and at 80°C Red: Rpf B spectrum acquired at 4°C 
Green: Rpf B spectrum acquired at 80°C. 
 
After unfolding the protein was brought back at 4°C, and a new set of temperature 
scan measurements was acquired to compare the propensity of Rpf B to refold after 
thermic unfolding. After the temperature scan from 80°C to 4°C a new spectrum was 
acquired for the protein after refolding. The figure 2.II.15 shows the overlay of the 
spectra before unfolding and after the protein was brought back in the initial 
temperature conditions. 
 61
 
     
 
 
Figure 2.II.16: Overlay of Rpf B’s spectra at 4°C before and after unfolding by temperature increase to 
80°C and refolding by decreasing the temperature to 4°C. In green is reported the spectrum acquired 
before unfolding and the spectrum acquired after refolding is reported in red. 
 
The spectrum of RpfB after refolding resembles that one measured before unfolding. 
This indicates that Rpf unfolding is rather reversible and the protein is quite stable. 
The same characterization was performed for Rpf Bcd, the shorter catalytic C-terminal 
domain of the protein Rpf B. Far-UV CD spectra were acquired in the same 
conditions used for the previous experiments. The spectrum reported below is for the 
domain at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.II.17: Far UV-CD spectrum of the domain Rpf Bcd at 20°C. 
 
 
Once the folding of the domain has been verified, a temperature scan was performed 
for this sample to investigate its stability. The wavelength was fixed at 208 nm, a 
typical α-helical folding value. The measurements were started at 5°C and the 
temperature increased to 80°C in 1 hour. 
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Figure 2.II.18: Rpf Bcd temperature scan measurements at 208 nm, between 5°C and 80°C. The 
protein domain is unfolded up to 60°C. 
 
A comparison between the spectrum acquired at 5°C and the spectrum acquired 
after unfolding at 80°C is reported in figure 2.II.18. 
 
 
 
 
 
 
 
 
Figure 2.II.19. Far UV-CD spectra overlay for the protein domain Rpf Bcd before (red) and after (blue) 
unfolding by increasing the temperature from 5°C to 80°C. 
After the unfolding the protein domain was brought back to 5°C and a new spectrum 
was acquired at 5°C to check protein folding. 
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Figure 2.II.20: Overlay spectra of Rpf Bcd before (red) and after (blue) unfolding (5°C-80°C) and 
refolding (80°C-5°C).The spectra are rather similar. 
From the circular dichroism studies so far reported it is possible to summarize that, 
as expected, all the Rpfs proteins considered in this study, possess an α-helical 
folding. As Rpf C preparation, here considered, is the less folded and shows a small 
amount aggregate, further studies are focused on the Rpf B and its catalytic domain.  
Furthermore Rpf B and Rpf Bcd are rather stable in buffer solution in the 
experimented conditions. This result is evidenced for these proteins from the 
unfolding/refolding study performed by CD. After unfolding, induced by temperature 
increase, the proteins both save the tendency to refold in almost the same α-helical 
folding, as the overlay of spectra acquired before and after the experiment shows. 
The folding of the protein, and its stability, is important both for further structural 
studies and for activity assays. 
 
 
 
 
 
 
 
 
 
 
Wavelenght (nm) 200   210 230 240 250 260 
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2.II.3.3. Rpf activity  
The mechanism of action proposed for lysozyme has been deduced from 
crystallographic and solution NMR studies by using the polymeric NAG substrate. It 
has been demonstrated that the active site of lysozyme can accommodate 6 units of 
NAG, the β(1-4) linked hexasaccharide of N-acetylglucosamine [52].  
Interestingly, it has been reported that the catalytic domain of Rpf B has no 
considerable muralytic activity  whereas a significant muralytic activity is shown by an 
homologous Rpf protein from the bacterium Micococcus luteus [43]. 
 
 
 
 
 
 
 
 
 
Figure 2.II.21: Multiple sequence alignment of Rpfs domain region from M. Tuberculosis and from M. 
luteus. Structure codes are from the Protein Data Bank (http://www.rcsb.org/pdb/) and sequence 
codes are from the M. tuberculosis genome for Rpf C (Rv1884c)and Rpf B (Rv1009). 
 
 
In view of the structural similarity of Rpf B to lysozyme and to Rpf from M. luteus the 
synthetic, artificial lysozyme substrate 4-methylumbelliferyl-β-D-N,N’,N”-
triacetylchitotriose (MUF tri-NAG) was used in this thesis study as a substrate for 
activity assays [53]. The choice of this substrate becomes from its fluorogenicity. Its 
cleavage produces a fluorescent compound and the assay may be performed by 
following the fluorescence produced by the reaction. The product of the catalytic 
reaction, 4-methylumbelliferone, has the maximum of fluorescence emission at 455 
nm. Therefore, the intensity of fluorescence has been monitored for 3-4 hours at 
37°C at 455 nm using an excitation wavelength of 360 nm. 
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Figure 2.II.22: Rpf B activity assay by fluorescence spectroscopy. a) The figure shows the spectrum 
acquired after 7 minutes incubation of the protein with the substrate MUF-tri NAG at 37°C. The higher 
curve (in red) is referred to the highest concentration of substrate (10 µM). b) The picture b shows the 
spectrum acquired after 3 hours incubation. The fluorescence intensity is reported in arbitrary units 
(u.a.) and increases up to 13900 u.a. 
 
Each eleven minutes acquisition, the fluorescence intensity measured at 455 nm was 
reported as function of the time to perform a kinetic of Rpf B activity assay. The 
points obtained are reported in the graphic in figure 2.II.22. 
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Figure 2.II.23: Rpf B muralytic activity measured by following the increasing fluorescence intensity at 
455 nm in 3 hours incubation of the protein with substrate at 37 °C. 
 
As shown in figure 2.II.22, fluorescence intensity increased over a three hours 
incubation at 37°C. This is evidence that 4-methylumbelliferone is released from the 
reaction and, consequently, that the protein tested is active. Different concentrations 
protein were also tested and the protein seems to work from 1:1 to 1:3 
protein/substrate molar ratio.  
During these experiments, for incubation times over 3 hours a decrease in 
fluorescence intensity was observed, and the samples were affected to evaporation 
from the plate wells. The plate used in this spectropolarimeter could not be covered 
and, for long incubation periods, the amount of reaction solution decreased to few 
microliters. Because of the impossibility to avoid these sample problems, the same 
experiment was performed in fluorescence cuvettes, with caps, on a Varian Cary 
Eclipse spectropolarimeter. Spectra acquired in 10 mm path length (500 µL volume) 
fluorescence cuvettes are reported for the protein Rpf B (2 µM) in the same buffer 
used for the previous experiment. In this new set of experiments the protein was 
incubated overnight at 37°C. 
 
 
 
 
 
 
 
 
 
 
Figure 2.II.24: Rpf B 2 µM fluorescence spectrum after and before overnight incubation at 37°C. 
These spectra were acquired in closed cuvettes in the same conditions used for the previous set of 
experiments. At the starting time the fluorescence intensity is about 3.7 a.u. After overnight incubation 
of the protein with the substrate the intensity of fluorescence is over 600 a.u. 
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The use of capped cuvettes allowed to avoid evaporation problems and to further 
verify Rpf B activity. In this experiments the fluorescence intensity reaches over 600 
u.a. for a protein concentration of 2.0 µM reacting with 20 µM MUF-tri NAG overnight. 
Further experiments are going to be performed to study Rpf B activity by 
fluorescence in order to define its reaction kinetic in cuvette and for longer time. 
 
 
3.     Conclusions and perspectives 
 
The interactions between biological macromolecules play a key role in almost all the 
biological mechanisms and pathways. Protein interactions are very specific and 
represent potential target points of pharmaceutical intervention and for devising new 
biotechnologically useful molecules to control pathological mechanisms. For this 
purposes, information are required about protein structural behaviour and their 
binding properties. 
In this thesis work, two important issues are developed: the role of protein-protein 
interactions in dysregulation of the apoptotic signal leading to MALT lymphoma, and 
the role of protein-cell wall interactions in Mycobacterium tuberculosis reactivation 
from latency. 
The first part of this study is dedicated to a complete investigation on the 
homodimerization of the human protein Bcl10, caused by homophilic interactions 
between “Caspase-Recruitment Domains” (CARD). This N-terminal domain is 
typically found in proteinaceous factors involved in cell signalling and, in particular, 
in proteins involved in the apoptotic cascade, such as Bcl10. The understanding of 
the dimerization mechanism, and how it can be modulated, is essential for the 
developing of tumour suppressor molecules. With this aim, the structural behaviour 
of the CARD domain was studied by focusing the investigation on the domain 
regions, potentially involved in CARD/CARD self-association. A preliminary study 
was carried out by circular dichroism techniques on the whole domain, to establish 
its global attitude to form homodimers and the influence of protein concentration in 
dimer formation. 
CARD domain exists in solution in two conformational states including a 
predominantly α-helical monomer, that is in equilibrium with a partially unfolded, 
dimeric form. This equilibrium is significantly shifted towards the monomeric form at 
micromolar concentrations. Surprisingly, at higher concentrations, the domain 
dimerizes and undergoes self-association with a concomitant increasing population 
of a partially unfolded form. The CARD/CARD interaction in this self-association is 
quite strong with a calculated Kd value of 18.6 µM. The dimeric form becomes 
significantly populated at concentrations higher than the Kd. CARD self-association, 
evidenced in this CD study, was in agreement with the gel filtration results, showing 
a concentration-dependent appearance of dimeric form.  
Furthermore, CARD self-association was successfully confirmed by ELISA assays 
by immobilizing the domain on the ELISA plate and verifying its binding to a biotin-
labelled CARD, using the biotin-streptavidin detection system. Then, in order to go 
deeper into CARD self-association and to determine which regions of the domain 
were potentially involved in the binding, CARD was hydrolyzed with trypsin and the 
digestion fractions, obtained by RP-HPLC, were employed in a competition ELISA 
assay. The competition properties of these fractions were verified in such a test by 
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comparing the binding attitude of the biotin-labelled CARD to the unlabelled CARD, 
with and without each digestion fraction. Four of these fractions were selected as 
positive-competing fractions in CARD-CARD binding and they were identified by LC-
MS to determine the regions involved in such interactions. The identified sequences 
were obtained as synthetic fragments and, so far, three peptide sequences, 
belonging to a specific domain region, were tested against the whole CARD in a 
new competition ELISA. The results show that the synthetic fragment, named as 
CARD [78-98] and its shorter analogue, CARD [91-98], are able to compete in 
CARD-CARD binding, confirming again their attitude in modulating CARD self-
association. Interestingly, the longer sequence CARD [68-98], belonging to the 
same binding region, shows the lowest competition in CARD binding. This evidence 
relates the binding property to a very specific region within the domain sequence. In 
order to provide a structure-function characterization of the identified region, the 
synthetic fragments CARD [78-98] and CARD [91-98], were characterized by 
circular dichroism. The longer peptide, which has reduced competition properties, 
shows no structural preferences and appears as unfolded while, the shorter 
analogue, CARD [78-98], which is able to compete in CARD binding, is rather folded 
in solution and shows a stable, α-helical folding. 
Even though Bcl10 CARD domain structure is not available, two similar CARDs, 
belonging to the proteins Apaf1 and RAIDD, were compared with Bcl10 CARD by 
using a sequence alignment program. The alignment of the fragment CARD [78-98] 
with RAIDD CARD shows that this fragment lies in a prevalently α-helical region, 
comprising the helix 5, the helix 6 and a short loop in between, confirming the 
structural behaviour determined in CD experiments.  
The results obtained in this thesis work provide a characterization and identification 
of one of the region sequences involved in Bcl10 CARD self-association, the 
fragment CARD [78-98]. 
Preliminary NMR studies were carried out on this peptide, in order to determine the 
best conditions for the NMR conformational characterization. In a concentration 
range between 1.0 mM and 0.1 mM (in H2O) at 25°C, a changing in the intensity and 
multiplicity of signals was observed, evidencing that, in this conditions, the peptide 
may exist as a complex mixture of different oligomeric states. 1D 1H NMR spectra, 
acquired for the peptide in 5mM Na acetate buffer pH=5.5, showed interestingly well 
resolved resonances and no aggregation behaviour at 0.1 mM concentration. These 
conditions were chosen to set up further two dimensional NMR experiments in order 
to determine peptide structure, and a complete characterization of the smaller 
fragment CARD [91-98] will be performed to verify the specificity of the sequence in 
the homophilic interaction. Then, with the aim to provide evidences towards the 
ability of this specific region to modulate Bcl10 filaments formation, in vitro 
experiments will be performed. Hence it has been demonstrated that filaments 
formation is due to CARD-CARD association between Bcl10 proteins, the 
employment of a peptide, specifically modulating such interaction, could provide the 
possibility to modulate the apoptotic signal in living cells.  
 
The second part of this thesis work is focused on the importance of protein-cell wall 
interactions in the transition of Mycobacterium tuberculosis from a latent state to a 
pathological state. There is no possibility to clear out the infection when the 
bacterium is in its dormant state. Therefore, any investigation on the causes of 
bacterial reactivation is important for the development of new therapies. Five 
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proteinaceous factors, called as “Resuscitation-Promoting Factors” (Rpf), are 
involved in the bacterial reactivation from “dormancy”. The role of Rpf proteins in the 
revival of dormant bacteria, still not clear, has been suggested to be the cleavage of 
oligosaccharides constituting the bacterial cell wall. All the studies reported so far in 
literature evidenced a muralytic activity, similar to that of the c-type lysozyme, for the 
Rpf from M. Luteus, but no evidences are reported for the M. tuberculosis Rpfs 
muralytic activity.  
In this thesis work, two of these proteins, the Rpf B and Rpf C, were selected. The 
proteins Rpf B, Rpf C and the catalytic domain Rpf Bcd were cloned, expressed and 
purified. Purification conditions were optimized to increase the solubility of the 
proteins and to avoid aggregates formation. The optimization is confirmed by gel 
filtration chromatograms and DLS measurements. 
In view of Rpf B’s structural similarity to lysozyme and in order to verify the muralytic 
activity of the protein, the synthetic, artificial lysozyme substrate 4-
methylumbelliferyl-β-D-N,N’,N”-triacetylchitotriose (MUF tri-NAG), was used as 
substrate for activity assays. This fluorogenic substrate produces a fluorescent 
compound (4-methylumbelliferone), whose maximum fluorescence emission is 
observed at 455 nm. The assay was performed by following for 4-5 hours at 37°C 
the increase of fluorescence intensity at 455 nm using an excitation wavelength of 
360 nm. Fluorescence intensity increased over a three hours incubation at 37°C. 
This is the evidence that 4-methylumbelliferone is released from the reaction and, 
consequently, that the protein tested possesses muralytic activity. Similar activity 
assays are in progress for the smaller domain Rpf Bcd . Interestingly, despite what is 
reported in the literature, this work has evidenced that RpfB possesses significant 
muralytic activity. Further studies will be aimed to design Rpfs’ inhibitors, which may 
prevent the pathogen to exit its dormant state. In vitro assays will be performed by 
screening a complete library of compounds, in order to identify those able to inhibit 
the muralytic activity observed so far on the synthetic, fluorogenic substrate of 
lysozyme, MUF tri-NAG. In addition to that experiments, in vivo assays could be 
made to test the ability of the protein to reactivate dormant cultures of 
Mycobacterium tuberculosis. 
A preliminary structural characterization of these proteins by circular dichroism 
revealed, for all of them, a prevalently α-helical folding in solution. Their fold is rather 
stable and their unfolding process is rather reversible. For a more detailed structural 
study, crystallization experiments of all Rpf here produced are in progress. The 
crystal structure of these proteins and of their complexes with substrate analogs and 
inhibitors will provide valuable information on the mechanism of action used by Rpfs 
to resuscitate dormant bacteria. 
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